<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408340</article-id><article-id pub-id-type="pmc">PMC12101703</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0321655</article-id><article-id pub-id-type="publisher-id">PONE-D-24-44674</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Neuroimaging</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuroimaging</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Virus Testing</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Clinical Laboratory Sciences</subject><subj-group><subject>Clinical Laboratories</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Vietnam</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Convolutional neural network using magnetic resonance brain imaging to predict outcome from tuberculosis meningitis</article-title><alt-title alt-title-type="running-head">Convolutional neural network using brain MRI to predict outcome from tuberculosis meningitis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4281-4929</contrib-id><name><surname>Dong</surname><given-names>Trinh Huu Khanh</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Canas</surname><given-names>Liane S.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Donovan</surname><given-names>Joseph</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Beasley</surname><given-names>Daniel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8733-692X</contrib-id><name><surname>Thuong-Thuong</surname><given-names>Nguyen Thuy</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Phu</surname><given-names>Nguyen Hoan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Nguyen Thi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ourselin</surname><given-names>Sebastien</given-names></name><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Razavi</surname><given-names>Reza</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Thwaites</surname><given-names>Guy E.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Modat</surname><given-names>Marc</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Oxford University Clinical Research Unit, Viet Nam</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>King&#x02019;s College London, United Kingdom</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>London School of Hygiene and Tropical Medicine, London, United Kingdom</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>the Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>School of Medicine, Vietnam National University &#x02013; Ho Chi Minh City, Viet Nam</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Graham</surname><given-names>Stephen Michael</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Melbourne, AUSTRALIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>trinhdhk@outlook.com.vn</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0321655</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Dong et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Dong et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0321655.pdf"/><abstract><sec id="sec021"><title>Introduction</title><p><italic toggle="yes">Tuberculous meningitis</italic> (TBM) leads to high mortality, especially amongst individuals with HIV. Predicting the incidence of disease-related complications is challenging, for which purpose the value of brain magnetic resonance imaging (MRI) has not been well investigated. We used a convolutional neural network (CNN) to explore the complementary contribution of brain MRI to the conventional prognostic determinants.</p></sec><sec id="sec022"><title>Methods</title><p>We pooled data from two randomised control trials of HIV-positive and HIV-negative adults with clinical TBM in Vietnam to predict the occurrence of death or new neurological complications in the first two months after the subject&#x02019;s first MRI session. We developed and compared three models: a logistic regression with clinical, demographic and laboratory data as reference, a CNN that utilised only T1-weighted MRI volumes, and a model that fused all available information. All models were fine-tuned using two repetitions of 5-fold cross-validation. The final evaluation was based on a random 70/30 training/test split, stratified by the outcome and HIV status. Based on the selected model, we explored the interpretability maps derived from the models.</p></sec><sec id="sec023"><title>Results</title><p>215 patients were included, with an event prevalence of 22.3%. On the test set our non-imaging model had higher AUC (71.2% <inline-formula id="pone.0321655.e001"><alternatives><graphic xlink:href="pone.0321655.e001.jpg" id="pone.0321655.e001g" position="anchor"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 1.1%) than the imaging-only model (67.3% <inline-formula id="pone.0321655.e002"><alternatives><graphic xlink:href="pone.0321655.e002.jpg" id="pone.0321655.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.6%). The fused model was superior to both, with an average AUC = 77.3% <inline-formula id="pone.0321655.e003"><alternatives><graphic xlink:href="pone.0321655.e003.jpg" id="pone.0321655.e003g" position="anchor"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.0% in the test set. The non-imaging variables were more informative in the HIV-positive group, while the imaging features were more predictive in the HIV-negative group. All three models performed better in the HIV-negative cohort. The interpretability maps show the model&#x02019;s focus on the lateral fissures, the corpus callosum, the midbrain, and peri-ventricular tissues.</p></sec><sec id="sec024"><title>Conclusion</title><p>Imaging information can provide added value to predict unwanted outcomes of TBM. However, to confirm this finding, a larger dataset is needed.</p></sec></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap>
</funding-source><award-id>215010/Z/18/Z</award-id><principal-award-recipient>
<name><surname>Thwaites</surname><given-names>Guy E.</given-names></name>
</principal-award-recipient></award-group><award-group id="award002"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100023312</institution-id><institution>Wellcome EPSRC Centre for Medical Engineering</institution></institution-wrap>
</funding-source><award-id>203148/Z/16/Z</award-id><principal-award-recipient>
<name><surname>Modat</surname><given-names>Marc</given-names></name>
</principal-award-recipient></award-group><award-group id="award003"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap>
</funding-source><award-id>225167/Z/22/Z</award-id><principal-award-recipient>
<name><surname>Thwaites</surname><given-names>Guy E.</given-names></name>
</principal-award-recipient></award-group><award-group id="award004"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap>
</funding-source><award-id>217650/Z/19/Z</award-id><principal-award-recipient>
<name><surname>Thwaites</surname><given-names>Guy E.</given-names></name>
</principal-award-recipient></award-group><award-group id="award005"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100023312</institution-id><institution>Wellcome EPSRC Centre for Medical Engineering</institution></institution-wrap>
</funding-source><award-id>EP/T022205/1</award-id><principal-award-recipient>
<name><surname>Modat</surname><given-names>Marc</given-names></name>
</principal-award-recipient></award-group><funding-statement>This project received funding from the Wellcome Trust, the Wellcome/EPSRC Centre for Medical Engineering (203148/Z/16/Z), the AI Centre for Value-Based Healthcare, the Vietnam ICU Translation Applications Laboratory (VITAL) consortium (217650/Z/19/Z, 215010/Z/18/Z, 225167/Z/22/Z) and Oxford University Clinical Research Unit. All processing was run on the EPSRCsupported (EP/T022205/1) Joint Academic Data Science Endeavour (JADE) HPC cluster. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data cannot be shared publicly because of various reasons. To make requests for data sharing, the researchers shall kindly contact Dr. Joseph Donovan (<email>joseph.donovan@lshtm.ac.uk</email>) or Prof. Guy Thwaites (<email>gthwaites@oucru.org</email>) for enquiries. For formal application, the researchers should detail their request on a request form as detailed on the OUCRU&#x02019;s data-sharing website (<ext-link xlink:href="https://www.oucru.org/data-sharing-policy/" ext-link-type="uri">https://www.oucru.org/data-sharing-policy/</ext-link>) and send to CTU@oucru.org.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data cannot be shared publicly because of various reasons. To make requests for data sharing, the researchers shall kindly contact Dr. Joseph Donovan (<email>joseph.donovan@lshtm.ac.uk</email>) or Prof. Guy Thwaites (<email>gthwaites@oucru.org</email>) for enquiries. For formal application, the researchers should detail their request on a request form as detailed on the OUCRU&#x02019;s data-sharing website (<ext-link xlink:href="https://www.oucru.org/data-sharing-policy/" ext-link-type="uri">https://www.oucru.org/data-sharing-policy/</ext-link>) and send to CTU@oucru.org.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p><italic toggle="yes">Tuberculous meningitis</italic> (TBM) is the most devastating form of tuberculosis, a disease caused by the dissemination of <italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">Mtb</italic>) into the central nervous system. It represents 2-5% of all cases of tuberculosis but kills 30%-50% of patients despite the best available anti-tuberculosis chemotherapy, with poorer outcomes especially associated with HIV coinfection [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0321655.ref003" ref-type="bibr">3</xref>]. Those who survive are often left with long-term neurological disability.</p><p>Most complications and deaths occur within two months of diagnosis and starting anti-tuberculosis treatment [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0321655.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0321655.ref005" ref-type="bibr">5</xref>]. Early identification of individuals at high risk of complications and death may facilitate more targeted monitoring and management. However, despite attempts, state-of-the-art predictive models have generally yielded areas under the curve (AUCs) of 76-77% [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0321655.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0321655.ref010" ref-type="bibr">10</xref>].</p><p>Many clinical and laboratory variables have been linked to poorer outcomes from TBM. Two of the strongest predictors are the Glasgow coma score (GCS), which assesses the degree of coma, and the British Medical Research Council (MRC) grade, which is based on the GCS and the presence of focal neurological deficit [<xref rid="pone.0321655.ref011" ref-type="bibr">11</xref>]. Other known predictors of poor outcomes are HIV coinfection with low CD4+ cell count and infection caused by multidrug-resistant bacteria [<xref rid="pone.0321655.ref012" ref-type="bibr">12</xref>]. Recent studies also suggest that host genotypic variation (e.g. in the Leukotriene A4 Hydrolase gene) may also influence intracerebral inflammation response and thus prognosis [<xref rid="pone.0321655.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0321655.ref013" ref-type="bibr">13</xref>].</p><p>Brain imaging has been used for decades in diagnosing and managing TBM [<xref rid="pone.0321655.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0321655.ref016" ref-type="bibr">16</xref>]. Its importance in clinical management has been widely accepted, with magnetic resonance imaging (MRI) being generally superior to computer tomography (CT) due to its greater ability to visualise small lesions, particularly in the brain stem and posterior fossa [<xref rid="pone.0321655.ref017" ref-type="bibr">17</xref>].</p><p>The ability of brain MRI to predict neurological complications and death is less well defined. The spectrum of neuro-radiological abnormalities caused by TBM varies across individuals, including hydrocephalus, contrast-enhancement of the basal meninges and cisterns, infarcts, and tuberculomas (<xref rid="pone.0321655.g001" ref-type="fig">Fig 1</xref>) [<xref rid="pone.0321655.ref012" ref-type="bibr">12</xref>]. These abnormalities are associated with more severe disease. For example, in a study from 2020 [<xref rid="pone.0321655.ref015" ref-type="bibr">15</xref>], 94% of 48 patients with MRC grade II and above had abnormalities on brain MRIs. In less severe cases, this proportion is reduced to 85% [<xref rid="pone.0321655.ref017" ref-type="bibr">17</xref>]. Two major limitations of MRI are its high cost and the dependence on manual, expert reading, which is slow and results in variability in interpretation, especially in low-resource settings. These low dimensional readings might also not be capable of capturing the whole spectrum of information available in an MRI volume and thus overlook minor but relevant characteristics.</p><fig position="float" id="pone.0321655.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.g001</object-id><label>Fig 1</label><caption><title>Typical findings on MRI - T1 MPRAGE: A: basal enhancement, vasculitis with thickened vascular walls, and hydrocephalus with dilated lateral ventricles; B: basal enhancement; C: tuberculoma (arrow); D: vasculitis</title></caption><graphic xlink:href="pone.0321655.g001" position="float"/></fig><p>Our study aims to evaluate the added predictive value of brain MRI information to predict the occurrence of any neurological complication within 60 days from the first imaging session. To our knowledge, this is the first attempt to employ imaging information to predict TBM outcomes automatically from baseline information data only.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Dataset</title><sec id="sec004"><title>Participants</title><p>Participants were recruited from two randomised control trials (RCTs, identifiers NCT03092817 and NCT03100786) enrolling adults with TBM (HIV-positive or -negative) admitted to the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam, from 25th May 2017 to 29th April 2021 [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0321655.ref021" ref-type="bibr">21</xref>]. Trial participants were treated with standard anti-tuberculosis drug therapy for 12 months, alongside a blinded 6-to-8-week tapering course of dexamethasone or placebo started at randomisation (with the exception of HIV-negative LTA4H TT-genotype participants in the LAST ACT trial who received open-label dexamethasone). All participants, or their relatives if they were incapacitated, provided written informed consent to enter the trials. The trials received ethical approvals from the Oxford Tropical Research Ethics Committee (approval numbers 36-16 and 52-16), the Vietnam Ministry of Health (approval numbers 38/CN-BDGDD, 108/CN-BDGDD, and 151/CN-BDGDD), and the HTD&#x02019;s local ethics committee (approval numbers 14/HDDD and 37/HDDD) [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>].</p><p>Trial participants were recruited into this study if they were at least 18 years old at the time of enrolment; with a clinical diagnosis of TBM, i.e., at least five days of meningitis symptoms, and cerebrospinal fluid (CSF) abnormalities; with anti-tuberculosis chemotherapy already started or planned by the treating clinician. Exclusion criteria included: an additional (non-TBM) brain infection confirmed or suspected by any applicable tests; more than six consecutive days of two or more drugs active against <italic toggle="yes">Mtb</italic> or more than three consecutive days of any type of orally or intravenously administered corticosteroid immediately before randomisation; dexamethasone considered mandatory or contra-indicated for any reason; or if the patient had previously been randomised into this trial for a prior episode of TBM; and lack of consent [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0321655.ref020" ref-type="bibr">20</xref>]. In this analysis, we only included participants enrolled up until 2021 and had at least one usable T1-weighted (T1w) MPRAGE MRI volume within the first month from enrolment.</p></sec><sec id="sec005"><title>Data collection</title><p>Data was frozen and curated for the analysis on 1st June 2021. Demographics (age, gender and HIV status) and relevant medical history were collected at baseline. Routinely during follow-up, a panel of relevant prognostic variables were recorded, including MRC grade, GCS and CSF biomarkers. The date of any new neurological event and death was documented (<xref rid="pone.0321655.t001" ref-type="table">Table 1</xref>) [<xref rid="pone.0321655.ref022" ref-type="bibr">22</xref>]. Lumbar puncture was performed according to the respective study protocols, from which cerebrospinal fluid white cell counts and differentials, protein, lactate, and glucose (with paired blood glucose) were acquired. TBM diagnosis was subsequently determined according to published criteria [<xref rid="pone.0321655.ref023" ref-type="bibr">23</xref>].</p><table-wrap position="float" id="pone.0321655.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.t001</object-id><label>Table 1</label><caption><title>Modified MRC Grading for TBM.</title></caption><alternatives><graphic xlink:href="pone.0321655.t001" id="pone.0321655.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Grade/Stage of TBM</th><th align="left" rowspan="1" colspan="1">Characteristics</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">GCS = 15, no focal neurology</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">GCS = 11-14 or GCS = 15 with any focal neurology</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="left" rowspan="1" colspan="1">GCS &#x0003c; 11</td></tr></tbody></table></alternatives></table-wrap><p>Brain MRIs were taken by either a Siemens MAGNETOM ESSENZA or AVANTO in one designated hospital in Ho Chi Minh City. Participants were images as near to the start of anti-tuberculosis chemotherapy as possible and within one month from the start of anti-tuberculosis chemotherapy unless contra-indicated. In this analysis, three-dimensional (3D) T1-weighted brain MRI scans were acquired with magnetisation-prepared rapid acquisition (T1w&#x02014;MPRAGE) pulse sequence. The scan&#x02019;s field of view was 168 <inline-formula id="pone.0321655.e004"><alternatives><graphic xlink:href="pone.0321655.e004.jpg" id="pone.0321655.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 256 <inline-formula id="pone.0321655.e005"><alternatives><graphic xlink:href="pone.0321655.e005.jpg" id="pone.0321655.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 160 voxels, with spatial resolution = 1.00&#x02009;mm <inline-formula id="pone.0321655.e006"><alternatives><graphic xlink:href="pone.0321655.e006.jpg" id="pone.0321655.e006g" position="anchor"/><mml:math id="M6" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 1.00&#x02009;mm <inline-formula id="pone.0321655.e007"><alternatives><graphic xlink:href="pone.0321655.e007.jpg" id="pone.0321655.e007g" position="anchor"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 1.15&#x02009;mm. We quality checked (QC) all imaging data visually for their field of view coverage and any acquisition artefacts. All MR sessions that did not pass the QC were excluded. If there were multiple T1w-MRPRAGE scans acquired and passed the QC, the scan taken closest to the enrolment date was selected into the study, ensuring one scan per participant. A patient was excluded if no T1w-MPRAGE scan was available or passed the manual QC.</p><p>Prior to the study, identifiable information, including participant identification number, age, date/time, and laboratory biomarkers were pseudonymised by value shifting and variable standardisation. The relevant metadata of every MR scan was also removed and inaccessible.</p></sec><sec id="sec006"><title>Feature encoding</title><p>Amongst all non-imaging features, continuous variables were centred (demeaned) and scaled by twice the empirical standard deviation [<xref rid="pone.0321655.ref024" ref-type="bibr">24</xref>]. Those with right-skewed empirical distributions were log-transformed before the scaling. Binary variables were one-hot encoded (i.e. 0 for Negative/No and 1 for Positive/Yes). Missing variables were imputed within the training process using Multivariate Imputation by Chained Equations (MICE) using predictive mean matching [<xref rid="pone.0321655.ref025" ref-type="bibr">25</xref>], implemented in the R statistical package <italic toggle="yes">mice</italic> [<xref rid="pone.0321655.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0321655.ref026" ref-type="bibr">26</xref>] and Python&#x02019;s <italic toggle="yes">scikit-learn</italic> [<xref rid="pone.0321655.ref027" ref-type="bibr">27</xref>].</p><p>All QC-passed MRI scans were first affine-registered into the 1mm isotropic MNI-template space [<xref rid="pone.0321655.ref028" ref-type="bibr">28</xref>] using NiftyReg package [<xref rid="pone.0321655.ref029" ref-type="bibr">29</xref>]. Registered volume dimensions were 180 <inline-formula id="pone.0321655.e008"><alternatives><graphic xlink:href="pone.0321655.e008.jpg" id="pone.0321655.e008g" position="anchor"/><mml:math id="M8" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 210 <inline-formula id="pone.0321655.e009"><alternatives><graphic xlink:href="pone.0321655.e009.jpg" id="pone.0321655.e009g" position="anchor"/><mml:math id="M9" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 180 voxels<sup>3</sup>. Spatially aligned scans were subsequently centre-cropped or -padded to 200 <inline-formula id="pone.0321655.e010"><alternatives><graphic xlink:href="pone.0321655.e010.jpg" id="pone.0321655.e010g" position="anchor"/><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 200 <inline-formula id="pone.0321655.e011"><alternatives><graphic xlink:href="pone.0321655.e011.jpg" id="pone.0321655.e011g" position="anchor"/><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 200 voxels<sup>3</sup> in size. Image intensities were normalised to range [0, 1] to provide a relatively equivalent range to non-imaging features [<xref rid="pone.0321655.ref024" ref-type="bibr">24</xref>]. Registered and normalised images were visually checked before inputted into the analysis.</p></sec></sec><sec id="sec007"><title>Experiments</title><sec id="sec008"><title>Objective and primary endpoint</title><p>The main objective of our study is to investigate the potential added values of imaging information in predicting the primary endpoint in TBM using early information from diagnostic time, complementing the state-of-the-art model which only uses conventional biomarkers [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>].</p><p>In this study, the primary outcome was defined as any new occurrence of neurological complications, including death, within 60 days of treatment, using information from the baseline. The outcome definition followed the primary endpoints defined in the two RCTs [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0321655.ref021" ref-type="bibr">21</xref>]. Accordingly, a non-mortal neurological event was defined as a reduction of GCS at least two units for at least 48 hours or any new focal neurological deficit that occurred within the first two months of treatment [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0321655.ref020" ref-type="bibr">20</xref>]. We developed different models to investigate how well this outcome was predicted by conventional clinical assessments and laboratory biomarkers (forming the non-imaging model, <inline-formula id="pone.0321655.e012"><alternatives><graphic xlink:href="pone.0321655.e012.jpg" id="pone.0321655.e012g" position="anchor"/><mml:math id="M12" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>), exclusively a brain MRI (which forms the imaging-only model, <inline-formula id="pone.0321655.e013"><alternatives><graphic xlink:href="pone.0321655.e013.jpg" id="pone.0321655.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>), and finally, the fusion of both sources of information (fused model, <inline-formula id="pone.0321655.e014"><alternatives><graphic xlink:href="pone.0321655.e014.jpg" id="pone.0321655.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>).</p></sec><sec id="sec009"><title>Non-imaging model</title><p>We built a logistic regression model (<inline-formula id="pone.0321655.e015"><alternatives><graphic xlink:href="pone.0321655.e015.jpg" id="pone.0321655.e015g" position="anchor"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) as a reference. Training for this reference model was done using the statistical package R, version 4.2.2 [<xref rid="pone.0321655.ref026" ref-type="bibr">26</xref>]. To enable a comparison with the literature, we only included features selected by a prior study, shared across HIV and non-HIV cohorts (<xref rid="pone.0321655.t002" ref-type="table">Table 2</xref> [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>]), briefly: age, weight, HIV status, GCS, MRC grade, CSF lymphocyte count, CSF glucose (with corresponding paired blood glucose), CSF protein, and CSF lactate. To promote generalisation, we added a Ridge regularisation term <inline-formula id="pone.0321655.e016"><alternatives><graphic xlink:href="pone.0321655.e016.jpg" id="pone.0321655.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> to the loss function of the model (i.e., Ridge regression, <xref rid="pone.0321655.e017" ref-type="disp-formula">Eq 1</xref>).</p><table-wrap position="float" id="pone.0321655.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.t002</object-id><label>Table 2</label><caption><title>Baseline characteristics, by HIV status.</title></caption><alternatives><graphic xlink:href="pone.0321655.t002" id="pone.0321655.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">Overall N = 215</th><th align="left" rowspan="1" colspan="1">HIV-negative N = 136</th><th align="left" rowspan="1" colspan="1">HIV-positive N = 79</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Event</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">48 (22%)</td><td align="left" rowspan="1" colspan="1">20 (15%)</td><td align="left" rowspan="1" colspan="1">28 (35%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">32 (24, 42)</td><td align="left" rowspan="1" colspan="1">34 (27, 48)</td><td align="left" rowspan="1" colspan="1">30 (24, 36)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">51 (47, 59)</td><td align="left" rowspan="1" colspan="1">53 (48, 60)</td><td align="left" rowspan="1" colspan="1">49 (45, 55)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">Local neurological deficit</td><td align="left" rowspan="1" colspan="1">212</td><td align="left" rowspan="1" colspan="1">29 (14%)</td><td align="left" rowspan="1" colspan="1">16 (12%)</td><td align="left" rowspan="1" colspan="1">13 (16%)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GCS</td><td align="left" rowspan="1" colspan="1">213</td><td align="left" rowspan="1" colspan="1">15 (14, 15)</td><td align="left" rowspan="1" colspan="1">15 (13, 15)</td><td align="left" rowspan="1" colspan="1">15 (14, 15)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MRC Grade</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; I</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">99 (46%)</td><td align="left" rowspan="1" colspan="1">62 (46%)</td><td align="left" rowspan="1" colspan="1">37 (47%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; II</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">106 (49%)</td><td align="left" rowspan="1" colspan="1">69 (51%)</td><td align="left" rowspan="1" colspan="1">37 (47%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; III</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10 (4.7%)</td><td align="left" rowspan="1" colspan="1">5 (3.7%)</td><td align="left" rowspan="1" colspan="1">5 (6.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CSF lymphocyte count (cells/<inline-formula id="pone.0321655.e023"><alternatives><graphic xlink:href="pone.0321655.e023" id="pone.0321655.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>L)</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">77 (50, 87)</td><td align="left" rowspan="1" colspan="1">81 (57, 87)</td><td align="left" rowspan="1" colspan="1">71 (32, 86)</td><td align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Median (1st, 3rd quartiles) for numeric variables; n (%) for categorical variables.</td></tr><tr><td align="left" colspan="6" rowspan="1">Comparison was done by Wilcoxon rank sum test for continuous variables and Pearson&#x02019;s Chi square test for categorical variables</td></tr><tr><td align="left" colspan="6" rowspan="1">Event is defined as any neurological event or death within 60 days of follow-up</td></tr></tbody></table></alternatives></table-wrap><p>Hence, we have</p><disp-formula id="pone.0321655.e017"><alternatives><graphic xlink:href="pone.0321655.e017.jpg" id="pone.0321655.e017g" position="anchor"/><mml:math id="M17" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mtext>expit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace linebreak="newline"/><mml:mtext>CE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>log</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>log</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace linebreak="newline"/><mml:mi>&#x02112;</mml:mi><mml:mo>=</mml:mo><mml:mtext>CE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">&#x02016;</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">&#x02016;</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(1)</label></disp-formula><p>where <italic toggle="yes">X</italic><sup><italic toggle="yes">T</italic></sup> is a vector of features whose coefficients were represented by vector <italic toggle="yes">w</italic>; <italic toggle="yes">X</italic><sup><italic toggle="yes">T</italic></sup><italic toggle="yes">w</italic> is termed the linear predictor; <italic toggle="yes">y</italic>&#x02009;=&#x02009;{<italic toggle="yes">y</italic><sub><italic toggle="yes">i</italic></sub>} and <inline-formula id="pone.0321655.e018"><alternatives><graphic xlink:href="pone.0321655.e018.jpg" id="pone.0321655.e018g" position="anchor"/><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> (<inline-formula id="pone.0321655.e019"><alternatives><graphic xlink:href="pone.0321655.e019.jpg" id="pone.0321655.e019g" position="anchor"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02264;</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x02264;</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>) are the observed binary outcome vector of length <italic toggle="yes">n</italic> and its corresponding predicted probability; <inline-formula id="pone.0321655.e020"><alternatives><graphic xlink:href="pone.0321655.e020.jpg" id="pone.0321655.e020g" position="anchor"/><mml:math id="M20" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> is the Ridge regularisation term. <inline-formula id="pone.0321655.e021"><alternatives><graphic xlink:href="pone.0321655.e021.jpg" id="pone.0321655.e021g" position="anchor"/><mml:math id="M21" display="inline" overflow="scroll"><mml:mrow><mml:mtext>CE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> is the cross-entropy loss and <inline-formula id="pone.0321655.e022"><alternatives><graphic xlink:href="pone.0321655.e022.jpg" id="pone.0321655.e022g" position="anchor"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x02112;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> is the total loss function that is optimised.</p></sec><sec id="sec010"><title>Incorporating imaging information</title><p>To embed imaging information into the prognostic model, we developed a neural network consisting of three components. First, MRIs were processed using an <italic toggle="yes">imaging features extractor</italic> that consisted of ten convolutional blocks and followed by one adaptive average pooling and one fully connected (FC) layer. Then, a separated shallow FC network was used to learn from the clinical and laboratory variables (<italic toggle="yes">non-imaging features extractor</italic>). Lastly, the <italic toggle="yes">imaging features extractor</italic> and <italic toggle="yes">non-imaging features extractor</italic> were fused into a three-FC-layer block, defined as the <italic toggle="yes">classifier</italic>. The overall architecture is shown in <xref rid="pone.0321655.g002" ref-type="fig">Fig 2</xref>.</p><fig position="float" id="pone.0321655.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.g002</object-id><label>Fig 2</label><caption><title>Proposed Fused CNN architecture.</title><p>The network comprises of two branches: Imaging feature extractor (1, green-top) and Non-imaging feature extractor (2, red-bottom). The output of (1) is a 512x[3x3x3] array, which was subsequently average pooled into a 512x1 vector. This vector is compressed into a 24x1 vector using a fully-connected layer before being concatenated with the 7x1 vector outputted from branch (2). The 31x1 concatenated vector is fed into a Classifier (3, violet-bottom), which performs the classification tasks. During the training, classification was performed on both branch-specific latent vectors (forming <inline-formula id="pone.0321655.e024"><alternatives><graphic xlink:href="pone.0321655.e024" id="pone.0321655.e024g" position="anchor"/><mml:math id="M24" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e025"><alternatives><graphic xlink:href="pone.0321655.e025" id="pone.0321655.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) and from the Classifier itself (forming <inline-formula id="pone.0321655.e026"><alternatives><graphic xlink:href="pone.0321655.e026" id="pone.0321655.e026g" position="anchor"/><mml:math id="M26" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>). However, in validation, only prediction from the Classifer was taken into account.</p></caption><graphic xlink:href="pone.0321655.g002" position="float"/></fig><p>Each block in the network consisted of one convolutional or linear layer, one drop-out layer, one normalisation layer, and one activation layer with Sigmoid Linear Unit (SiLU [<xref rid="pone.0321655.ref030" ref-type="bibr">30</xref>]) as the activation function, in that order. Apart from the first convolutional block of the <italic toggle="yes">imaging features extractor</italic>, every downsampling convolutional block (with stride = 2) was followed directly by an equi-resolution convolutional block (stride = 1). We used Instance Normalisation for the first three convolutional blocks and Batch Normalisation for the rest. 512 channels outputted from the <italic toggle="yes">imaging features extractor</italic> were averaged and flattened into a vector of 512 features before being compressed into a latent vector of length 24 using a fully-connected layer. No drop-out layer was used at the output block. The output layer has 2 dimensions corresponding to the two outcome classes.</p><p>We first experimented with an imaging-only model with only this latent vector fed into the <italic toggle="yes">classifier</italic>, forming <inline-formula id="pone.0321655.e027"><alternatives><graphic xlink:href="pone.0321655.e027.jpg" id="pone.0321655.e027g" position="anchor"/><mml:math id="M27" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. This allowed us to explore the predictive value of imaging data alone in the context of missing other features. We finally incorporated clinical and laboratory features by concatenating the learnt information to the extracted imaging features (forming a latent vector of length 31) before feeding it into the <italic toggle="yes">classifier</italic> (<inline-formula id="pone.0321655.e028"><alternatives><graphic xlink:href="pone.0321655.e028.jpg" id="pone.0321655.e028g" position="anchor"/><mml:math id="M28" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>).</p><p>Similarly to the non-imaging model, we used cross-entropy loss (<xref rid="pone.0321655.e017" ref-type="disp-formula">Eq 1</xref>) with Sigmoid (expit) as the output activation function, denoted as <inline-formula id="pone.0321655.e029"><alternatives><graphic xlink:href="pone.0321655.e029.jpg" id="pone.0321655.e029g" position="anchor"/><mml:math id="M29" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. We, however, did not implement the Ridge penalty <inline-formula id="pone.0321655.e030"><alternatives><graphic xlink:href="pone.0321655.e030.jpg" id="pone.0321655.e030g" position="anchor"/><mml:math id="M30" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> into the model. In its stead, a weight decay penalisation was used. To facilitate the extraction of relevant information and ensure equivalent attention to both imaging and non-imaging data, we also performed this classification task directly from the <italic toggle="yes">imaging features extractor</italic> and <italic toggle="yes">non-imaging features extractor</italic>. These auxiliary tasks were only used for training and were not considered during inference. The overall loss used for training was the weighted sum of the main loss <inline-formula id="pone.0321655.e031"><alternatives><graphic xlink:href="pone.0321655.e031.jpg" id="pone.0321655.e031g" position="anchor"/><mml:math id="M31" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and the two auxiliary losses (<inline-formula id="pone.0321655.e032"><alternatives><graphic xlink:href="pone.0321655.e032.jpg" id="pone.0321655.e032g" position="anchor"/><mml:math id="M32" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e033"><alternatives><graphic xlink:href="pone.0321655.e033.jpg" id="pone.0321655.e033g" position="anchor"/><mml:math id="M33" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) (<xref rid="pone.0321655.e035" ref-type="disp-formula">Eq 2</xref>). For simplicity, in our study, we fixed <inline-formula id="pone.0321655.e034"><alternatives><graphic xlink:href="pone.0321655.e034.jpg" id="pone.0321655.e034g" position="anchor"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b1;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>.</p><disp-formula id="pone.0321655.e035"><alternatives><graphic xlink:href="pone.0321655.e035.jpg" id="pone.0321655.e035g" position="anchor"/><mml:math id="M35" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi>&#x02112;</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mi>&#x02112;</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(2)</label></disp-formula></sec><sec id="sec011"><title>Model tuning, validation, and inferences of the selected model</title><p>All models were optimised using the Joint Academic Data Science Endeavour (JADE) II cluster, with NVIDIA Tesla V100 32 GB GPUs. Before training, the total dataset was split into 30% for final assessment (herein denoted as test set) and 70% for training and validation (denoted as training set). The splitting was stratified by the response variable and HIV status. We used NovoGrad [<xref rid="pone.0321655.ref031" ref-type="bibr">31</xref>] as the training optimiser.</p><p>Optimiser configurations (learning rate (LR) initial value and LR scheduler) and regularisation terms (<inline-formula id="pone.0321655.e036"><alternatives><graphic xlink:href="pone.0321655.e036.jpg" id="pone.0321655.e036g" position="anchor"/><mml:math id="M36" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> for <inline-formula id="pone.0321655.e037"><alternatives><graphic xlink:href="pone.0321655.e037.jpg" id="pone.0321655.e037g" position="anchor"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> or dropout probability and weight decay for <inline-formula id="pone.0321655.e038"><alternatives><graphic xlink:href="pone.0321655.e038.jpg" id="pone.0321655.e038g" position="anchor"/><mml:math id="M38" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e039"><alternatives><graphic xlink:href="pone.0321655.e039.jpg" id="pone.0321655.e039g" position="anchor"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) were tuned by a grid search utilising two repetitions of 5-fold cross-validation on the training set (<xref rid="pone.0321655.s001" ref-type="supplementary-material">S1 Fig</xref>). We selected the best model based on the average AUC and cross-entropy loss estimated on a pooled validation set. This pooled validation set was created by stacking the prediction and ground truth from ten left-out parts. The definition for each hyper-parameter is given in <xref rid="pone.0321655.s002" ref-type="supplementary-material">S1 Table</xref>.</p><p>At the first step of training, MRI scans were randomly augmented by (1) random flipping, (2) random affine transformation (shearing, scaling, rotation, and translation) along the three dimensions, (3) random intensity shifting and scaling, (4) coarse patch cropping, and (5) noise addition. The probability and magnitudes of each type of transformation were fine-tuned as hyper-parameters (<xref rid="pone.0321655.s003" ref-type="supplementary-material">S2 Table</xref>). All augmentations were implemented using the MONAI package, version 1.0 [<xref rid="pone.0321655.ref032" ref-type="bibr">32</xref>].</p><p>To perform a final assessment for the models, we froze parameter values at the best-generalised epochs and evaluated on the 30% held-out test set. To correct for the improper Loss function used in <inline-formula id="pone.0321655.e040"><alternatives><graphic xlink:href="pone.0321655.e040.jpg" id="pone.0321655.e040g" position="anchor"/><mml:math id="M40" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e041"><alternatives><graphic xlink:href="pone.0321655.e041.jpg" id="pone.0321655.e041g" position="anchor"/><mml:math id="M41" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (<xref rid="pone.0321655.e035" ref-type="disp-formula">Eq 2</xref>), we recalibrated the model by fitting an intercept-only logistic regression on the observed class and the predicted scores as the offset. We compared between different models the AUC and scaled Brier score (also called explained variation or index of predictive accuracy - IPA, Eq <xref rid="pone.0321655.e045" ref-type="disp-formula">4</xref>) and balanced accuracy (BA, <xref rid="pone.0321655.e043" ref-type="disp-formula">Eq 3</xref>). Informal non-parametric Friedman Rank Sum tests and pairwise Durbin-Conover tests between model performances were also reported. Where possible, p-values were adjusted for multiplicity using Holm&#x02019;s method [<xref rid="pone.0321655.ref033" ref-type="bibr">33</xref>]. The Scaled Brier score is a validation score to measure the accuracy of probabilistic predictions [<xref rid="pone.0321655.ref034" ref-type="bibr">34</xref>]. In brief,</p><disp-formula id="pone.0321655.e042">
<alternatives><graphic xlink:href="pone.0321655.e042.jpg" id="pone.0321655.e042g" position="anchor"/><mml:math id="M42" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>BA</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives>
</disp-formula><disp-formula id="pone.0321655.e043"><alternatives><graphic xlink:href="pone.0321655.e043.jpg" id="pone.0321655.e043g" position="anchor"/><mml:math id="M43" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mfrac><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(3)</label></disp-formula><disp-formula id="pone.0321655.e044">
<alternatives><graphic xlink:href="pone.0321655.e044.jpg" id="pone.0321655.e044g" position="anchor"/><mml:math id="M44" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives>
</disp-formula><disp-formula id="pone.0321655.e045"><alternatives><graphic xlink:href="pone.0321655.e045.jpg" id="pone.0321655.e045g" position="anchor"/><mml:math id="M45" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>IPA</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(4)</label></disp-formula><p>where <inline-formula id="pone.0321655.e046"><alternatives><graphic xlink:href="pone.0321655.e046.jpg" id="pone.0321655.e046g" position="anchor"/><mml:math id="M46" display="inline" overflow="scroll"><mml:mrow><mml:mtext>B</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula> is the Brier score, <italic toggle="yes">y</italic><sub><italic toggle="yes">i</italic></sub>&#x02009;=&#x02009;0,1 is the observed binary outcome, <inline-formula id="pone.0321655.e047"><alternatives><graphic xlink:href="pone.0321655.e047.jpg" id="pone.0321655.e047g" position="anchor"/><mml:math id="M47" display="inline" overflow="scroll"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#x02264;</mml:mo><mml:msub><mml:mover><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02264;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> is the predicted risk <italic toggle="yes">P</italic>(<italic toggle="yes">y</italic><sub><italic toggle="yes">i</italic></sub>&#x02009;=&#x02009;1) given model <inline-formula id="pone.0321655.e048"><alternatives><graphic xlink:href="pone.0321655.e048.jpg" id="pone.0321655.e048g" position="anchor"/><mml:math id="M48" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover><mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. <inline-formula id="pone.0321655.e049"><alternatives><graphic xlink:href="pone.0321655.e049.jpg" id="pone.0321655.e049g" position="anchor"/><mml:math id="M49" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> is the Brier score of the null model, i.e., the model that does not include any covariables (an intercept-only model). An IPA = 0 means that the model&#x02019;s performance is identical to that of the Null model (no benefit gained). The best value is 1 (the model has perfect prediction). An IPA &#x0003c; 0 happens when the use of the model is even more harmful than a random guess.</p><p>The classification threshold to quantify BA was chosen based on the apparent prevalence of the primary endpoint [<xref rid="pone.0321655.ref035" ref-type="bibr">35</xref>]. We reported the mean and variability of these performance metrics across models fit on 10 folds, in which:</p><list list-type="bullet"><list-item><p>Validation-based metrics were measured on the corresponding left-out validation sets (i.e., 1/5 of the training parts).</p></list-item><list-item><p>Test-based metrics were measured on the unseen test dataset (i.e., 30% of the whole sample).</p></list-item></list><p>Finally, based on this selected model configuration, we performed an exploratory analysis on voxel-wise contributions by using Smooth Gradient-based Saliency maps (SmoothGrad, [<xref rid="pone.0321655.ref036" ref-type="bibr">36</xref>]). The procedure, implemented in MONAI, combines guided back-propagation technique with Gaussian noise smoothing to produce a heatmap of feature importance, on the voxel level. This enabled us to explore which regions in the brain were most focused on by the model and thus provided us with some suggestive points for future research.</p></sec></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>Baseline characteristics</title><p>The baseline characteristics of the population are summarised in <xref rid="pone.0321655.t002" ref-type="table">Table 2</xref>. Amongst 264 participants admitted to HTD from two studies and had baseline information collected, 215 individuals were selected into the analysis. 49 participants were excluded from the analysis due to missing or unrecoverable artefacts in baseline MRIs. In the remaining population, 56 individuals were held out for testing (<xref rid="pone.0321655.g003" ref-type="fig">Fig 3</xref>).</p><fig position="float" id="pone.0321655.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.g003</object-id><label>Fig 3</label><caption><title>Patient recruitment profile.</title></caption><graphic xlink:href="pone.0321655.g003" position="float"/></fig><p>The observed prevalence of new neurological events, including death, was 22.3%. Median age was 32 years with a 1st-3rd inter-quartile range of (24, 42) years. About half of the curated cohorts were in a mild stage, with 46% participants in MRC Grade I at enrolment and Median GCS = 15.</p><p>Out of 215 analysed participants, 79 individuals (36.7%) were infected with HIV. There were slightly more patients with MRC grade III in the HIV-positive group (6.3% than in the HIV-negative cohort (3.7%). However the difference was not statistically significant (p-value = 0.6).</p><p>Compared with HIV-negative participants, there was a considerably higher occurrence of event among those with HIV (35.4% and 14.7%, respectively, p-value &#x0003c; 0.001), in which a lower age and CSF lymphocyte count were also observed. There were no other apparent differences between the two HIV cohorts in our dataset.</p><p>At the time of the analysis, among 215 participants, two had missing Glasgow Coma Score (0.9%), three had missing local neurological deficit (1.4%), and eight had missing CSF lymphocyte count (3.7%) (<xref rid="pone.0321655.t002" ref-type="table">Table 2</xref>). As outlined in Section Materials and Method, these missing data were imputed per iteration using PMM method as part of the training process [<xref rid="pone.0321655.ref025" ref-type="bibr">25</xref>].</p><p><xref rid="pone.0321655.t003" ref-type="table">Table 3</xref> outlined the distributions of the outcome and non-imaging covariables between our training (N=159) and test (N=56) set. Overall, there was no considerable difference between the two cohorts (unadjusted p &#x0003e; 0.1 for all comparisons).</p><table-wrap position="float" id="pone.0321655.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.t003</object-id><label>Table 3</label><caption><title>Baseline characteristics, by data spliting to 70% training/validation and 30% testing.</title></caption><alternatives><graphic xlink:href="pone.0321655.t003" id="pone.0321655.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">Training N = 159</th><th align="left" rowspan="1" colspan="1">Test N = 56</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Event</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">37 (23%)</td><td align="left" rowspan="1" colspan="1">11 (20%)</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV Status</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; HIV-negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">100 (63%)</td><td align="left" rowspan="1" colspan="1">36 (64%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; HIV-positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">59 (37%)</td><td align="left" rowspan="1" colspan="1">20 (36%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">52 (47, 60)</td><td align="left" rowspan="1" colspan="1">50 (46, 55)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Local neurological deficit</td><td align="left" rowspan="1" colspan="1">212</td><td align="left" rowspan="1" colspan="1">19 (12%)</td><td align="left" rowspan="1" colspan="1">10 (19%)</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GCS</td><td align="left" rowspan="1" colspan="1">213</td><td align="left" rowspan="1" colspan="1">15 (14, 15)</td><td align="left" rowspan="1" colspan="1">15 (13, 15)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MRC Grade</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; I</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">74 (47%)</td><td align="left" rowspan="1" colspan="1">25 (45%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; II</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">179 (50%)</td><td align="left" rowspan="1" colspan="1">27 (48%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; III</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 (3.8%)</td><td align="left" rowspan="1" colspan="1">4 (7.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CSF lymphocyte count (cells/<inline-formula id="pone.0321655.e050"><alternatives><graphic xlink:href="pone.0321655.e050" id="pone.0321655.e050g" position="anchor"/><mml:math id="M50" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>L)</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">77 (50, 87)</td><td align="left" rowspan="1" colspan="1">72 (49, 86)</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (Missing)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Median (1st, 3rd quartiles) for numeric variables; n (%) for categorical variables.</td></tr><tr><td align="left" colspan="5" rowspan="1">Comparision was done by Wilcoxon rank sum test for continuous variables and Pearson&#x02019;s Chi square test for categorical variables</td></tr><tr><td align="left" colspan="5" rowspan="1">Event is defined as any neurological event or death within 60 days of follow-up</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec014"><title>Model selection and performance</title><p>Chosen hyper-parameter values for data augmentation resulting from our grid search are shown in <xref rid="pone.0321655.s003" ref-type="supplementary-material">S2 Table</xref>. In general, models which were trained under small but frequent augmentation had better generalisation than those with large but scarce augmentation. After the grid search, the optimal value for Ridge regularisation term in <inline-formula id="pone.0321655.e051"><alternatives><graphic xlink:href="pone.0321655.e051.jpg" id="pone.0321655.e051g" position="anchor"/><mml:math id="M51" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was found at <inline-formula id="pone.0321655.e052"><alternatives><graphic xlink:href="pone.0321655.e052.jpg" id="pone.0321655.e052g" position="anchor"/><mml:math id="M52" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, whereas the optimal weight decays for <inline-formula id="pone.0321655.e053"><alternatives><graphic xlink:href="pone.0321655.e053.jpg" id="pone.0321655.e053g" position="anchor"/><mml:math id="M53" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e054"><alternatives><graphic xlink:href="pone.0321655.e054.jpg" id="pone.0321655.e054g" position="anchor"/><mml:math id="M54" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> were found at 0.12 for each feature extractor and 0.2 for the <italic toggle="yes">Classifier</italic>. In the same order, optimal dropout probabilities were 0.25 and 0.5. LR was initialised at <inline-formula id="pone.0321655.e055"><alternatives><graphic xlink:href="pone.0321655.e055.jpg" id="pone.0321655.e055g" position="anchor"/><mml:math id="M55" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mspace width="0.167em"/><mml:mrow><mml:mi>&#x000d7;</mml:mi></mml:mrow><mml:mspace width="0.167em"/><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> and was decayed by 5 times (<inline-formula id="pone.0321655.e056"><alternatives><graphic xlink:href="pone.0321655.e056.jpg" id="pone.0321655.e056g" position="anchor"/><mml:math id="M56" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x003b3;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>) every k = 400 epochs.</p><p>On the pooled validation dataset, both imaging-only and fused models showed comparable AUCs, with an average of 77% for <inline-formula id="pone.0321655.e057"><alternatives><graphic xlink:href="pone.0321655.e057.jpg" id="pone.0321655.e057g" position="anchor"/><mml:math id="M57" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and 78.2% for <inline-formula id="pone.0321655.e058"><alternatives><graphic xlink:href="pone.0321655.e058.jpg" id="pone.0321655.e058g" position="anchor"/><mml:math id="M58" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (<xref rid="pone.0321655.t004" ref-type="table">Table 4</xref> and <xref rid="pone.0321655.g004" ref-type="fig">Fig 4A</xref>). Both models were apparently superior to <inline-formula id="pone.0321655.e059"><alternatives><graphic xlink:href="pone.0321655.e059.jpg" id="pone.0321655.e059g" position="anchor"/><mml:math id="M59" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (AUC = 60.7%). The same trend was shown with scaled Brier score (IPA) and the BA at the threshold based on event prevalence = 22% (herein denoted as just BA), with an increase from 55.2% in <inline-formula id="pone.0321655.e060"><alternatives><graphic xlink:href="pone.0321655.e060.jpg" id="pone.0321655.e060g" position="anchor"/><mml:math id="M60" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> to 66.4% in the fused model.</p><table-wrap position="float" id="pone.0321655.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.t004</object-id><label>Table 4</label><caption><title>Performances of the non-imaging, imaging-only, and fused model after fine-tuning, on the validation and test set. For each type of model, the performance metrics (AUC and IPA) and their variation were estimated based on <italic toggle="yes">n</italic>&#x02009;=&#x02009;10 models optimized on <italic toggle="yes">n</italic>&#x02009;=&#x02009;10 folds.</title></caption><alternatives><graphic xlink:href="pone.0321655.t004" id="pone.0321655.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Model</th><th align="left" colspan="3" rowspan="1">Validation set</th><th align="left" colspan="3" rowspan="1">Test set</th></tr><tr><th align="left" rowspan="1" colspan="1">(%)</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">IPA</th><th align="left" rowspan="1" colspan="1">BA</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">IPA</th><th align="left" rowspan="1" colspan="1">BA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e067">
<alternatives><graphic xlink:href="pone.0321655.e067" id="pone.0321655.e067g" position="anchor"/><mml:math id="M67" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>clin</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">60.7 <inline-formula id="pone.0321655.e068"><alternatives><graphic xlink:href="pone.0321655.e068" id="pone.0321655.e068g" position="anchor"/><mml:math id="M68" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 10.6</td><td align="left" rowspan="1" colspan="1">22.3 <inline-formula id="pone.0321655.e069"><alternatives><graphic xlink:href="pone.0321655.e069" id="pone.0321655.e069g" position="anchor"/><mml:math id="M69" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 17.4</td><td align="left" rowspan="1" colspan="1">58.1 <inline-formula id="pone.0321655.e070"><alternatives><graphic xlink:href="pone.0321655.e070" id="pone.0321655.e070g" position="anchor"/><mml:math id="M70" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 7.0</td><td align="left" rowspan="1" colspan="1">71.2 <inline-formula id="pone.0321655.e071"><alternatives><graphic xlink:href="pone.0321655.e071" id="pone.0321655.e071g" position="anchor"/><mml:math id="M71" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 1.1</td><td align="left" rowspan="1" colspan="1">34.2 <inline-formula id="pone.0321655.e072"><alternatives><graphic xlink:href="pone.0321655.e072" id="pone.0321655.e072g" position="anchor"/><mml:math id="M72" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 0.5</td><td align="left" rowspan="1" colspan="1">62.5 <inline-formula id="pone.0321655.e073"><alternatives><graphic xlink:href="pone.0321655.e073" id="pone.0321655.e073g" position="anchor"/><mml:math id="M73" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e074">
<alternatives><graphic xlink:href="pone.0321655.e074" id="pone.0321655.e074g" position="anchor"/><mml:math id="M74" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>img</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">77.0 <inline-formula id="pone.0321655.e075"><alternatives><graphic xlink:href="pone.0321655.e075" id="pone.0321655.e075g" position="anchor"/><mml:math id="M75" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 5.4</td><td align="left" rowspan="1" colspan="1">29.1 <inline-formula id="pone.0321655.e076"><alternatives><graphic xlink:href="pone.0321655.e076" id="pone.0321655.e076g" position="anchor"/><mml:math id="M76" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 9.0</td><td align="left" rowspan="1" colspan="1">70.3 <inline-formula id="pone.0321655.e077"><alternatives><graphic xlink:href="pone.0321655.e077" id="pone.0321655.e077g" position="anchor"/><mml:math id="M77" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 7.9</td><td align="left" rowspan="1" colspan="1">67.3 <inline-formula id="pone.0321655.e078"><alternatives><graphic xlink:href="pone.0321655.e078" id="pone.0321655.e078g" position="anchor"/><mml:math id="M78" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.6</td><td align="left" rowspan="1" colspan="1">31.1 <inline-formula id="pone.0321655.e079"><alternatives><graphic xlink:href="pone.0321655.e079" id="pone.0321655.e079g" position="anchor"/><mml:math id="M79" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 3.6</td><td align="left" rowspan="1" colspan="1">61.7 <inline-formula id="pone.0321655.e080"><alternatives><graphic xlink:href="pone.0321655.e080" id="pone.0321655.e080g" position="anchor"/><mml:math id="M80" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e081">
<alternatives><graphic xlink:href="pone.0321655.e081" id="pone.0321655.e081g" position="anchor"/><mml:math id="M81" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>fused</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">78.2 <inline-formula id="pone.0321655.e082"><alternatives><graphic xlink:href="pone.0321655.e082" id="pone.0321655.e082g" position="anchor"/><mml:math id="M82" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.3</td><td align="left" rowspan="1" colspan="1">31.5 <inline-formula id="pone.0321655.e083"><alternatives><graphic xlink:href="pone.0321655.e083" id="pone.0321655.e083g" position="anchor"/><mml:math id="M83" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 8.4</td><td align="left" rowspan="1" colspan="1">70.5 <inline-formula id="pone.0321655.e084"><alternatives><graphic xlink:href="pone.0321655.e084" id="pone.0321655.e084g" position="anchor"/><mml:math id="M84" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.0</td><td align="left" rowspan="1" colspan="1">77.3 <inline-formula id="pone.0321655.e085"><alternatives><graphic xlink:href="pone.0321655.e085" id="pone.0321655.e085g" position="anchor"/><mml:math id="M85" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.0</td><td align="left" rowspan="1" colspan="1">37.3 <inline-formula id="pone.0321655.e086"><alternatives><graphic xlink:href="pone.0321655.e086" id="pone.0321655.e086g" position="anchor"/><mml:math id="M86" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.9</td><td align="left" rowspan="1" colspan="1">68.6 <inline-formula id="pone.0321655.e087"><alternatives><graphic xlink:href="pone.0321655.e087" id="pone.0321655.e087g" position="anchor"/><mml:math id="M87" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.4</td></tr><tr><td align="left" colspan="7" rowspan="1">Values are in the format &#x0201d;Mean (sd)&#x0201d; across 10 models.</td></tr><tr><td align="left" colspan="7" rowspan="1">Balanced Accuracy and IPA were calculated at 22% (event prevalence)</td></tr><tr><td align="left" colspan="7" rowspan="1">AUC: area under the ROC curve. IPA: index of predictive accuracy. BA: balanced accuracy</td></tr></tbody></table></alternatives></table-wrap><fig position="float" id="pone.0321655.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.g004</object-id><label>Fig 4</label><caption><title>Performance of our model against validation and test datasets.</title><p>Each model was trained n=10 times on 10 cross-validated folds of the 2 repeated 5-fold cross-validations. A, B: Average ROC curves on validation and test datasets, stratified by models. C, D: Box plots of AUCs on validation and test datasets across folds, stratified by models. E, F: Box plots of scaled Brier scores on validation and test datasets across folds, stratified by models.</p></caption><graphic xlink:href="pone.0321655.g004" position="float"/></fig><p>The fold-wise comparison of AUC (<xref rid="pone.0321655.g004" ref-type="fig">Fig 4C</xref>) and Scaled Brier score (IPA, <xref rid="pone.0321655.g004" ref-type="fig">Fig 4E</xref>) showed a significant difference in performances between three models (Friedman&#x02019;s p-value &#x0003c; 0.001 for IPA and p-value = 0.01 for AUC). Post hoc pairwise comparisons showed a leap in performance from <inline-formula id="pone.0321655.e061"><alternatives><graphic xlink:href="pone.0321655.e061.jpg" id="pone.0321655.e061g" position="anchor"/><mml:math id="M61" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> to <inline-formula id="pone.0321655.e062"><alternatives><graphic xlink:href="pone.0321655.e062.jpg" id="pone.0321655.e062g" position="anchor"/><mml:math id="M62" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (with adjusted Durbin-Conover&#x02019;s p-value = 0.005 for AUC and adjusted p-value &#x0003c; 0.0001 for IPA). However, the AUC of <inline-formula id="pone.0321655.e063"><alternatives><graphic xlink:href="pone.0321655.e063.jpg" id="pone.0321655.e063g" position="anchor"/><mml:math id="M63" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> widely varied across different folds with minimum AUC as low as 58% and highest AUC surpassing <inline-formula id="pone.0321655.e064"><alternatives><graphic xlink:href="pone.0321655.e064.jpg" id="pone.0321655.e064g" position="anchor"/><mml:math id="M64" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> with AUC &#x0003e; 90% (<xref rid="pone.0321655.g004" ref-type="fig">Fig 4C</xref>). The fold-based IPAs of <inline-formula id="pone.0321655.e065"><alternatives><graphic xlink:href="pone.0321655.e065.jpg" id="pone.0321655.e065g" position="anchor"/><mml:math id="M65" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> were more stable and consistently lower than those of <inline-formula id="pone.0321655.e066"><alternatives><graphic xlink:href="pone.0321655.e066.jpg" id="pone.0321655.e066g" position="anchor"/><mml:math id="M66" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (<xref rid="pone.0321655.g004" ref-type="fig">Fig 4E</xref>).</p><p>On the test dataset (N = 56), <inline-formula id="pone.0321655.e088"><alternatives><graphic xlink:href="pone.0321655.e088.jpg" id="pone.0321655.e088g" position="anchor"/><mml:math id="M88" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> still performed the best on average amongst the three with AUC = 77.3% and BA = 66.4% (<xref rid="pone.0321655.t004" ref-type="table">Table 4</xref>). <inline-formula id="pone.0321655.e089"><alternatives><graphic xlink:href="pone.0321655.e089.jpg" id="pone.0321655.e089g" position="anchor"/><mml:math id="M89" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> had a lower AUC and IPA but higher BA compared with <inline-formula id="pone.0321655.e090"><alternatives><graphic xlink:href="pone.0321655.e090.jpg" id="pone.0321655.e090g" position="anchor"/><mml:math id="M90" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. Different from the pooled validation set, <xref rid="pone.0321655.t004" ref-type="table">Table 4</xref> also demonstrated that, across all metrics on the test set, <inline-formula id="pone.0321655.e091"><alternatives><graphic xlink:href="pone.0321655.e091.jpg" id="pone.0321655.e091g" position="anchor"/><mml:math id="M91" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was the most stable with minimal variation across different folds.</p><p>The difference between the validation dataset and test dataset also holds for fold-wise comparisons (<xref rid="pone.0321655.g004" ref-type="fig">Fig 4D</xref> &#x00026; F), in which Friedman&#x02019;s p-value &#x0003c; 0.001 for both IPA and AUC. <inline-formula id="pone.0321655.e092"><alternatives><graphic xlink:href="pone.0321655.e092.jpg" id="pone.0321655.e092g" position="anchor"/><mml:math id="M92" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> showed a superior AUC (adjusted Durbin-Conover&#x02019;s p-value = 0.005) and IPA (adjusted Durbin-Conover&#x02019;s p-value = 0.01) compared with <inline-formula id="pone.0321655.e093"><alternatives><graphic xlink:href="pone.0321655.e093.jpg" id="pone.0321655.e093g" position="anchor"/><mml:math id="M93" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. Both models apparently had poorer discriminative value than <inline-formula id="pone.0321655.e094"><alternatives><graphic xlink:href="pone.0321655.e094.jpg" id="pone.0321655.e094g" position="anchor"/><mml:math id="M94" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (adjusted Durbin-Conover&#x02019;s p-values &#x0003c; 0.001 for AUC), with some suggestive indication of a gain in IPA between <inline-formula id="pone.0321655.e095"><alternatives><graphic xlink:href="pone.0321655.e095.jpg" id="pone.0321655.e095g" position="anchor"/><mml:math id="M95" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0321655.e096"><alternatives><graphic xlink:href="pone.0321655.e096.jpg" id="pone.0321655.e096g" position="anchor"/><mml:math id="M96" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (adjusted Durbin-Conover&#x02019;s p-value = 0.24).</p><p><xref rid="pone.0321655.t005" ref-type="table">Table 5</xref> shows the model evaluation on the test dataset, stratified by cohorts. In the HIV-negative cohort (N = 36), it is suggested that <inline-formula id="pone.0321655.e097"><alternatives><graphic xlink:href="pone.0321655.e097.jpg" id="pone.0321655.e097g" position="anchor"/><mml:math id="M97" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> had slightly lower AUC slightly higher IPA than <inline-formula id="pone.0321655.e098"><alternatives><graphic xlink:href="pone.0321655.e098.jpg" id="pone.0321655.e098g" position="anchor"/><mml:math id="M98" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. BA of <inline-formula id="pone.0321655.e099"><alternatives><graphic xlink:href="pone.0321655.e099.jpg" id="pone.0321655.e099g" position="anchor"/><mml:math id="M99" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was 55.4% <inline-formula id="pone.0321655.e100"><alternatives><graphic xlink:href="pone.0321655.e100.jpg" id="pone.0321655.e100g" position="anchor"/><mml:math id="M100" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.2%, apparently lower than that of <inline-formula id="pone.0321655.e101"><alternatives><graphic xlink:href="pone.0321655.e101.jpg" id="pone.0321655.e101g" position="anchor"/><mml:math id="M101" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (67.3% <inline-formula id="pone.0321655.e102"><alternatives><graphic xlink:href="pone.0321655.e102.jpg" id="pone.0321655.e102g" position="anchor"/><mml:math id="M102" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.3%). Both models were consistently inferior to <inline-formula id="pone.0321655.e103"><alternatives><graphic xlink:href="pone.0321655.e103.jpg" id="pone.0321655.e103g" position="anchor"/><mml:math id="M103" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (AUC = 84.1% and BA = 35.3).</p><table-wrap position="float" id="pone.0321655.t005"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.t005</object-id><label>Table 5</label><caption><title>Performances of the non-imaging, imaging-only, and fused model on test set (N=56), stratified by HIV status. For each type of model, the performance metrics (AUC and IPA) and their variation were estimated based on n=10 models optimised on n=10 folds.</title></caption><alternatives><graphic xlink:href="pone.0321655.t005" id="pone.0321655.t005g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Model</th><th align="left" colspan="3" rowspan="1">HIV-positive (p=35%)</th><th align="left" colspan="3" rowspan="1">HIV-negative (p=15%)</th></tr><tr><th align="left" rowspan="1" colspan="1">(%)</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">IPA</th><th align="left" rowspan="1" colspan="1">BA</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">IPA</th><th align="left" rowspan="1" colspan="1">BA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e115">
<alternatives><graphic xlink:href="pone.0321655.e115" id="pone.0321655.e115g" position="anchor"/><mml:math id="M115" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>clin</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">64.3 <inline-formula id="pone.0321655.e116"><alternatives><graphic xlink:href="pone.0321655.e116" id="pone.0321655.e116g" position="anchor"/><mml:math id="M116" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 13.7</td><td align="left" rowspan="1" colspan="1">8.3 <inline-formula id="pone.0321655.e117"><alternatives><graphic xlink:href="pone.0321655.e117" id="pone.0321655.e117g" position="anchor"/><mml:math id="M117" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.2</td><td align="left" rowspan="1" colspan="1">59.2 <inline-formula id="pone.0321655.e118"><alternatives><graphic xlink:href="pone.0321655.e118" id="pone.0321655.e118g" position="anchor"/><mml:math id="M118" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 5.7</td><td align="left" rowspan="1" colspan="1">71.8 <inline-formula id="pone.0321655.e119"><alternatives><graphic xlink:href="pone.0321655.e119" id="pone.0321655.e119g" position="anchor"/><mml:math id="M119" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 10.7</td><td align="left" rowspan="1" colspan="1">48.5 <inline-formula id="pone.0321655.e120"><alternatives><graphic xlink:href="pone.0321655.e120" id="pone.0321655.e120g" position="anchor"/><mml:math id="M120" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 5.5</td><td align="left" rowspan="1" colspan="1">55.4 <inline-formula id="pone.0321655.e121"><alternatives><graphic xlink:href="pone.0321655.e121" id="pone.0321655.e121g" position="anchor"/><mml:math id="M121" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e122">
<alternatives><graphic xlink:href="pone.0321655.e122" id="pone.0321655.e122g" position="anchor"/><mml:math id="M122" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>img</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">57.0 <inline-formula id="pone.0321655.e123"><alternatives><graphic xlink:href="pone.0321655.e123" id="pone.0321655.e123g" position="anchor"/><mml:math id="M123" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.1</td><td align="left" rowspan="1" colspan="1">5.0 <inline-formula id="pone.0321655.e124"><alternatives><graphic xlink:href="pone.0321655.e124" id="pone.0321655.e124g" position="anchor"/><mml:math id="M124" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.2</td><td align="left" rowspan="1" colspan="1">52.7 <inline-formula id="pone.0321655.e125"><alternatives><graphic xlink:href="pone.0321655.e125" id="pone.0321655.e125g" position="anchor"/><mml:math id="M125" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 8.9</td><td align="left" rowspan="1" colspan="1">74.4 <inline-formula id="pone.0321655.e126"><alternatives><graphic xlink:href="pone.0321655.e126" id="pone.0321655.e126g" position="anchor"/><mml:math id="M126" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 3.5</td><td align="left" rowspan="1" colspan="1">45.6 <inline-formula id="pone.0321655.e127"><alternatives><graphic xlink:href="pone.0321655.e127" id="pone.0321655.e127g" position="anchor"/><mml:math id="M127" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 4.1</td><td align="left" rowspan="1" colspan="1">67.3 <inline-formula id="pone.0321655.e128"><alternatives><graphic xlink:href="pone.0321655.e128" id="pone.0321655.e128g" position="anchor"/><mml:math id="M128" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0321655.e129">
<alternatives><graphic xlink:href="pone.0321655.e129" id="pone.0321655.e129g" position="anchor"/><mml:math id="M129" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mtext>fused</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="1" colspan="1">66.5 <inline-formula id="pone.0321655.e130"><alternatives><graphic xlink:href="pone.0321655.e130" id="pone.0321655.e130g" position="anchor"/><mml:math id="M130" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 5.5</td><td align="left" rowspan="1" colspan="1">11.7 <inline-formula id="pone.0321655.e131"><alternatives><graphic xlink:href="pone.0321655.e131" id="pone.0321655.e131g" position="anchor"/><mml:math id="M131" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.8</td><td align="left" rowspan="1" colspan="1">53.3 <inline-formula id="pone.0321655.e132"><alternatives><graphic xlink:href="pone.0321655.e132" id="pone.0321655.e132g" position="anchor"/><mml:math id="M132" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.8</td><td align="left" rowspan="1" colspan="1">84.1 <inline-formula id="pone.0321655.e133"><alternatives><graphic xlink:href="pone.0321655.e133" id="pone.0321655.e133g" position="anchor"/><mml:math id="M133" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.4</td><td align="left" rowspan="1" colspan="1">51.5 <inline-formula id="pone.0321655.e134"><alternatives><graphic xlink:href="pone.0321655.e134" id="pone.0321655.e134g" position="anchor"/><mml:math id="M134" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.5</td><td align="left" rowspan="1" colspan="1">77.3 <inline-formula id="pone.0321655.e135"><alternatives><graphic xlink:href="pone.0321655.e135" id="pone.0321655.e135g" position="anchor"/><mml:math id="M135" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 6.1</td></tr><tr><td align="left" colspan="7" rowspan="1">Values are in the format &#x0201c;Mean (sd)&#x0201d; across 10 models.</td></tr><tr><td align="left" colspan="7" rowspan="1">Balanced Accuracy and IPA were calculated at 22% (event prevalence)</td></tr><tr><td align="left" colspan="7" rowspan="1">AUC: area under the ROC curve. IPA: index of predictive accuracy. BA: balanced accuracy</td></tr></tbody></table></alternatives></table-wrap><p>On the contrary, among participants with HIV (N = 20), <inline-formula id="pone.0321655.e104"><alternatives><graphic xlink:href="pone.0321655.e104.jpg" id="pone.0321655.e104g" position="anchor"/><mml:math id="M104" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> had better accuracy of 59.2% <inline-formula id="pone.0321655.e105"><alternatives><graphic xlink:href="pone.0321655.e105.jpg" id="pone.0321655.e105g" position="anchor"/><mml:math id="M105" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 5.7% than our fused model (53.3% <inline-formula id="pone.0321655.e106"><alternatives><graphic xlink:href="pone.0321655.e106.jpg" id="pone.0321655.e106g" position="anchor"/><mml:math id="M106" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#x000b1;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> 2.8%). However, the former still had marginally lower IPA and lower AUC than <inline-formula id="pone.0321655.e107"><alternatives><graphic xlink:href="pone.0321655.e107.jpg" id="pone.0321655.e107g" position="anchor"/><mml:math id="M107" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. <inline-formula id="pone.0321655.e108"><alternatives><graphic xlink:href="pone.0321655.e108.jpg" id="pone.0321655.e108g" position="anchor"/><mml:math id="M108" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> apparently performed worst in this cohort, with AUC = 57% and BA = 66%.</p><p>The AUC of all three models were higher in HIV-negative cohorts, with AUC = 71.8% for <inline-formula id="pone.0321655.e109"><alternatives><graphic xlink:href="pone.0321655.e109.jpg" id="pone.0321655.e109g" position="anchor"/><mml:math id="M109" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, marginally lower than <inline-formula id="pone.0321655.e110"><alternatives><graphic xlink:href="pone.0321655.e110.jpg" id="pone.0321655.e110g" position="anchor"/><mml:math id="M110" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (74.4%) and considerably lower than <inline-formula id="pone.0321655.e111"><alternatives><graphic xlink:href="pone.0321655.e111.jpg" id="pone.0321655.e111g" position="anchor"/><mml:math id="M111" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (84.1%). The same trend was observed for IPA, where three models were considerably more predictive in this cohort (with IPA <inline-formula id="pone.0321655.e112"><alternatives><graphic xlink:href="pone.0321655.e112.jpg" id="pone.0321655.e112g" position="anchor"/><mml:math id="M112" display="inline" overflow="scroll"><mml:mrow><mml:mo>&#x02248;</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> 45-50%) compared to the HIV-positive group (with IPA <inline-formula id="pone.0321655.e113"><alternatives><graphic xlink:href="pone.0321655.e113.jpg" id="pone.0321655.e113g" position="anchor"/><mml:math id="M113" display="inline" overflow="scroll"><mml:mrow><mml:mo>&#x02248;</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> 5-11%). The only exception was that BA of <inline-formula id="pone.0321655.e114"><alternatives><graphic xlink:href="pone.0321655.e114.jpg" id="pone.0321655.e114g" position="anchor"/><mml:math id="M114" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> amongst HIV-negative patients was lower than the other (55.4% vs. 59.2%).</p></sec><sec id="sec015"><title>Inferences on relevant features of the selected model</title><p>The saliency maps produced by SmoothGrad [<xref rid="pone.0321655.ref037" ref-type="bibr">37</xref>] demonstrate which voxels contribute the most to the decision of the <inline-formula id="pone.0321655.e136"><alternatives><graphic xlink:href="pone.0321655.e136.jpg" id="pone.0321655.e136g" position="anchor"/><mml:math id="M136" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> via a 3D heatmap. Each sub-figure (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5</xref>) shows a 2D slice of MRI scans included in the training set, overlaid by the colour representing the level of importance of the regions to the decision, from blue to red. In general, the post hoc analysis showed a strong focus around the inner area of the cerebrum (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5A</xref>,<xref rid="pone.0321655.g005" ref-type="fig">5C</xref>), arguably the white matter. Also found to be important to the model&#x02019;s decision was the grey matter area around the Sylvian fissures, which overlapped with the frontmost region of the temporal lobe (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5D</xref>, green arrows), the lateral and third ventricles (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5A</xref>,<xref rid="pone.0321655.g005" ref-type="fig">5B</xref>,<xref rid="pone.0321655.g005" ref-type="fig">5D</xref>). Sub-figure A and B also highlighted some peri-ventricular brain regions, in particular the corpus callosum, the caudate nucleus, and the midbrain area (green arrows). An indistinguishable part in the cerebellum and the pons-medulla combination made a strong but not consistent contribution (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5A</xref>,<xref rid="pone.0321655.g005" ref-type="fig">5B</xref>, purple arrows).</p><fig position="float" id="pone.0321655.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0321655.g005</object-id><label>Fig 5</label><caption><title>Sample saliency maps showing several regions guiding the model, on sagittal and transversal planes.</title><p>The redder the pixel, the more it contributed to the prediction. The model focused on the corpus callosum (A, green arrow), cerebellum (A, purple arrow), brain stem (B, green and purple arrows), and temporal lobe around Sylvian fisure (D, green arrows). The enhanced basal meninges and tuberculomas (orange arrows) did not provide a strong contribution to the decision.</p></caption><graphic xlink:href="pone.0321655.g005" position="float"/></fig><p>In contrast, the existence of tuberculomas and enhancement of the basal meninges only provided a weak contribution to the model&#x02019;s decision and appeared as dark blue regions on the heatmap (<xref rid="pone.0321655.g005" ref-type="fig">Fig 5B</xref>,<xref rid="pone.0321655.g005" ref-type="fig">5C</xref>, orange arrows). A stronger but still weakly highlighted tuberculoma was marked on <xref rid="pone.0321655.g005" ref-type="fig">Fig 5A</xref> (orange arrow). In general, however, the boundaries between strong and weak signal regions were unclear and not specific to any particular anatomical region of the brain.</p></sec></sec><sec sec-type="conclusions" id="sec016"><title>Discussion</title><p>With high mortality rate, forecasting TBM progress has been considered a question of utmost clinical importance. However, despite decades-long research, this still a huge clinical challenge. The search for potential prognostic biomarkers have been continuing, with high cost, but minimal success. Contradictorily, the use of magnetic resonance images (MRIs) in outcome prediction is very limited, mainly due to the lack of an efficient method to fully handle such a complicated type of biomarker.</p><p>Our study aimed to investigate this modality with data-driven techniques. Leveraging convolutional neural network, we has shown evidence for the added prognostic value of MRIs to predict the poor outcome of TBM, independently and in conjuction with standard-of-care prognostic features. We developed and compared three models: one with only clinical information (<inline-formula id="pone.0321655.e137"><alternatives><graphic xlink:href="pone.0321655.e137.jpg" id="pone.0321655.e137g" position="anchor"/><mml:math id="M137" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>), one with only MRI-extracted information (<inline-formula id="pone.0321655.e138"><alternatives><graphic xlink:href="pone.0321655.e138.jpg" id="pone.0321655.e138g" position="anchor"/><mml:math id="M138" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>), and the other where both information was fused (<inline-formula id="pone.0321655.e139"><alternatives><graphic xlink:href="pone.0321655.e139.jpg" id="pone.0321655.e139g" position="anchor"/><mml:math id="M139" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>). The models performed well on unseen data, demonstrating their clinical value and potential.</p><p>Our findings have shown evidence that MRI alone can predict poor TBM outcome on parity with conventional biomarkers (with balanced accuracy = 61.7% for <inline-formula id="pone.0321655.e140"><alternatives><graphic xlink:href="pone.0321655.e140.jpg" id="pone.0321655.e140g" position="anchor"/><mml:math id="M140" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> and 62.5% for <inline-formula id="pone.0321655.e141"><alternatives><graphic xlink:href="pone.0321655.e141.jpg" id="pone.0321655.e141g" position="anchor"/><mml:math id="M141" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>). This strongly suggested that there were signals associated with TBM outcomes in both data types. Their predictive signals did not fully overlap, as when combining two modalities, <inline-formula id="pone.0321655.e142"><alternatives><graphic xlink:href="pone.0321655.e142.jpg" id="pone.0321655.e142g" position="anchor"/><mml:math id="M142" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> effectively gained 6.1% in both balanced accuracy and AUC, and 3.1% in IPA.</p><p>Stratified by HIV status, it is also suggestive that, in the HIV-negative group, imaging information alone could provide marginally better performance than the non-imaging counterpart, effectively gaining 2.6% in AUC and 11.9% in BA. Combining both modalities increased 12.3% in AUC and 21.9% in BA. In general, all models performed considerably better in the HIV-negative cohort. This is potentially because of less variance in the progression of TBM among the HIV-negative cohort.</p><p>Conversely, amongst patients coinfected with HIV, conventional biomarkers may play a more decisive role in predicting patient outcome, and the inclusion of imaging data did not contribute much to the prediction AUC (<xref rid="pone.0321655.t005" ref-type="table">Table 5</xref>). One explanation could be that mortality in HIV-positive patients was more prominently driven by underlying comorbidities than just tuberculous complications on the brain alone. A notable point is that although the accuracy of <inline-formula id="pone.0321655.e143"><alternatives><graphic xlink:href="pone.0321655.e143.jpg" id="pone.0321655.e143g" position="anchor"/><mml:math id="M143" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> is marginally lower than <inline-formula id="pone.0321655.e144"><alternatives><graphic xlink:href="pone.0321655.e144.jpg" id="pone.0321655.e144g" position="anchor"/><mml:math id="M144" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> in this cohort, the AUC and IPA of the fused model were still higher than those of the non-imaging one. This can be interpreted that, although there might not be an accuracy gain in this cohort when the fused model made the right decision, it was made with higher confidence. Regardless, the limited test sample size for the HIV-positive cohort (N = 20) could also be a factor hindering any conclusive comparison. Furthermore, these results are purely descriptive without rigid statistical testing and, therefore, should be considered informal. However, further investigation could open a new insight and opportunity for TBM research.</p><p>The diagnostic and prognostic value of biomarkers based on MRIs have been studied in TBM for a long time [<xref rid="pone.0321655.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0321655.ref038" ref-type="bibr">38</xref>], but with limited success. Neural networks, albeit powerful, by their black-box nature provide little understanding of the association between predictors and outcomes, which may hamper the confidence in practice and the transfer of knowledge. In this study, SmoothGrad algorithm allowed us to look into the decision-making process of the model, with minimal assumptions. Leveraging this technique, our study found some brain areas relevant in predicting TBM outcomes, on voxel level, and ranked them by importance. Some findings including the contribution of hydrocephalus are consistent with prior findings in the literature, thus increasing our confidence in their validity.</p><p>There are, however, some contradictory areas. In particular, despite being clinically believed to be a sign of poor prognosis, the existence of tuberculomas and the enhancement of the basal meninges were not associated with bad outcomes. This can be due to the scarcity and the variability of these lesions, especially tuberculomas. Clinically, the prognostic impact of tuberculomas can vary depend on their position. For instance, their &#x0201c;mass effect&#x0201d; - a medical phenomenon caused by an alien structure pushing and displacing its surrounding tissue - can be harmless when appearing on the white matter region, but can cause an autonomous system disruption when appearing in the important body such as the brain stem or hypothalamus, as detected in <xref rid="pone.0321655.g005" ref-type="fig">Fig 5A</xref>, orange arrow. Under the limited amount of samples, our model might have failed to capture this position-dependent association. This essentially leaves room for improvement for future research.</p><p>An intriguing finding is the focus on the Sylvian fissures and the frontmost parts of the temporal lobe, the midbrain, the medulla oblongata, and the corpus callosum. These areas are important brain bodies that maintain the vital functions of the body. The temporal lobe provides a wide range of perceptive functions, including emotion, sensing, hearing, and memory generation, while the corpus callosum is believed to be bridging the two brain sides. The midbrain, the pons, and the medulla oblongata are parts of the brainstem, which coordinate various aspects of sensory and motor processing. The midbrain controls visual and auditory reflexes and is integral for motor coordination, linking the cerebellum and cerebrum. The pons acts as a relay station between the cerebrum and cerebellum, playing a key role in motor control, balance, eye movement and facial expressions and is essential for respiratory rhythm. The medulla oblongata is vital for autonomic functions, especially the cardiovascular and respiratory systems.</p><p>Any impact on these particular structures, as a consequence, has the potential to reduce cognition - which is associated with GCS, MRC Grade, and the neurological complication as defined in the primary endpoints - and autonomous dysfunction - including diabetes insipidus, hyponatremia, or the syndrome of inappropriate anti-diuretic hormone secretion (SIADH). All of these syndromes are believed to be severe complications of TBM and substantially contribute to the risk of death. These findings are consistent with the prior study where plasma sodium levels have been short-listed as an important risk factor of 9-month mortality [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>] and with the pathological beliefs around TBM. By exploring these visual patterns, we could acquire better insight into the regional targets of the disease and thus develop customized treatment strategies.</p><p>Compared to a recent survival model by Thao et al. [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>], our reference non-imaging model has inferior performance (AUC = 71.2% vs. 77&#x02013;78%). There are several explanations for this. The first could be due to the lack of CD4+ count as a predictor in the HIV-positive group. Another potential reason is that we did not include patients who had died prematurely before any MRI scans were acquired. These patients were likely to be severe and hence presented with clear signals. The impact of this selection also notably reduced the prevalence of the outcome of interest to 22% (15% for HIV-negative and 35% for HIV-positive patients), considerably lower than the reported prevalence (1/3 for HIV-negative and 1/2 for HIV-positive patients) in other studies [<xref rid="pone.0321655.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0321655.ref003" ref-type="bibr">3</xref>]. The last potential explanation is that we ignored the effect of dexamethasone on mortality at two months. This was due to the ongoing status of the RCTs at the time of analysis. Although the most recent report from the HIV-positive cohort [<xref rid="pone.0321655.ref039" ref-type="bibr">39</xref>] did not show any statistically significant difference between the two treatment arms, this unadjusted variable could have induced unwanted variance and could be considered a limitation that hampered our performance.</p><p>Other limitations were also expected. First, although the original RCTs took place in the two largest tertiary hospitals in Ho Chi Minh City, Viet Nam [<xref rid="pone.0321655.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0321655.ref020" ref-type="bibr">20</xref>], only participants at one site (HTD) were acquired in our analysis. The results from this study thus did not take into account the variation across different sites, although there was not expected to be one, as implied in the analysis plan and the report of ACT HIV [<xref rid="pone.0321655.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0321655.ref039" ref-type="bibr">39</xref>]. Additionally, as discussed above, the limited dataset size included in the analysis increases the risk of overfitting.</p><p>The standard deviation of performance metrics also indicated a large variability across the different validation sets and across the validation and test datasets. Interestingly, the non-imaging model varied the most in the validation sets but stabilized in the test set. This is likely induced by the limited size of the validation sets (32 subjects), which possibly was too small to represent the whole training sample. One additional factor could be the regularization term we used in this model. Better stability was witnessed in the other two models where we imposed a strong regularization to promote generalizability. Such strong regularization, however, inevitably harmed the overall performance [<xref rid="pone.0321655.ref040" ref-type="bibr">40</xref>] as can be observed with the performance drop between the validation and the testing sets (<xref rid="pone.0321655.g004" ref-type="fig">Fig 4</xref>).</p><p>Finally, despite the consistency with past knowledge, our interpretation on the saliency maps was limited. The translation from voxel to brain region carried some level of uncertainty and subjectivity, especially when the boundary between critical and less important areas was fuzzy. A more rigid analysis based on brain segmentation is therefore necessary to confirm these findings.</p><p>One strong point of our study lays within the uniqueness of the dataset we acquired. Our datasets came from two large RCTs conducted in Southern Viet Nam dedicated to the prognosis of TBM. Every participant was tested for HIV before enrollment. Clinical and laboratory biomarkers were collected and rigorously monitored during follow-up with minimal missing data. This considerably raised the validity, reliability and statistical power of our analysis.</p><p>Another novelty in our study is the automatic extraction of MRI biomarkers in a fully data-driven manner, without depending on manual reading from radiologists. This helps the clinicians across different sites in making an objective decision. On the technical side, this study can be considered an example of incorporating multi-modal information. Leveraging fused convolutional neural network architectures and state-of-the-art techniques, we developed an end-to-end model that automatically extracts and incorporates imaging information in combination with conventional clinical and laboratory features to predict the occurrence of neurological complications, including death, within 60 days after the first imaging session. To our knowledge, this is among the first works that utilize imaging signals in a fully automatic way to improve the prognosis prediction of TBM, complementing the work by Canas et al. [<xref rid="pone.0321655.ref041" ref-type="bibr">41</xref>] on predicting the long-term sequelae among TBM patients. The findings in our studies have paved the way for further investigation of TBM brain imaging.</p><p>In conclusion, our study has presented a new approach to predict poor TBM outcomes, using imaging in combination with conventional biomarkers. We have shown evidence for the complementary value of MRI in predicting the survival of TBM in conjunction with conventional biomarkers. In critical conditions like TBM that affect, accurate patient triage is highly beneficial, especially in low-middle-income countries. Our study also found sound indicative regions associated with poor outcomes, paving the way to improve the understanding of disease pathology and increase clinical confidence in the prediction. To further confirm our findings, a larger study is necessary.</p></sec><sec id="sec017"><title>List of VITAL investigators</title><p><italic toggle="yes">Oxford University Clinical Research Unit, Viet Nam</italic>: Dong Huu Khanh Trinh*, Dang Phuong Thao, Dang Trung Kien, Doan Bui Xuan Thy, Du Hong Duc, Ronald Geskus, Ho Bich Hai, Ho Quang Chanh, Ho Van Hien, Huynh Trung Trieu, Evelyne Kestelyn, Lam Minh Yen, Le Dinh Van Khoa, Le Thanh Phuong, Le Thuy Thuy Khanh, Luu Hoai Bao Tran, Luu Phuoc An, Angela Mcbride, Nguyen Lam Vuong, Nguyen Quang Huy, Nguyen Than Ha Quyen, Nguyen Thanh Ngoc, Nguyen Thi Giang, Nguyen Thi Diem Trinh, Nguyen Thi Le Thanh, Nguyen Thi Phuong Dung, Nguyen Thi Phuong Thao, Ninh Thi Thanh Van, Pham Tieu Kieu, Phan Nguyen Quoc Khanh, Phung Khanh Lam, Phung Tran Huy Nhat, Guy Thwaites, Louise Thwaites, Tran Minh Duc, Trinh Manh Hung, Hugo Turner, Jennifer Ilo Van Nuil, Vo Tan Hoang, Vu Ngo Thanh Huyen, Sophie Yacoub,</p><p><italic toggle="yes">The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam</italic>: Cao Thi Tam, Duong Bich Thuy, Ha Thi Hai Duong, Ho Dang Trung Nghia, Le Buu Chau, Le Mau Toan, Le Ngoc Minh Thu, Le Thi Mai Thao, Luong Thi Hue Tai, Nguyen Hoan Phu, Nguyen Quoc Viet, Nguyen Thanh Dung, Nguyen Thanh Nguyen, Nguyen Thanh Phong, Nguyen Thi Kim Anh, Nguyen Van Hao, Nguyen Van Thanh Duoc, Pham Kieu Nguyet Oanh, Phan Thi Hong Van, Phan Tu Qui, Phan Vinh Tho, Truong Thi Phuong Thao</p><p><italic toggle="yes">University of Oxford, Oxford, UK</italic>: Natasha Ali, David Clifton, Mike English, Jannis Hagenah, Ping Lu, Jacob McKnight, Chris Paton, Tingting Zhu</p><p><italic toggle="yes">Imperial College London, London, UK</italic>: Pantelis Georgiou, Bernard Hernandez Perez, Kerri Hill-Cawthorne, Alison Holmes, Stefan Karolcik, Damien Ming, Nicolas Moser, Jesus Rodriguez Manzano</p><p><italic toggle="yes">King&#x02019;s College London, London, UK</italic>: Liane Canas, Alberto Gomez, Hamideh Kerdegari, Andrew King, Marc Modat, Reza Razavi, Miguel Xochicale</p><p><italic toggle="yes">Ulm University, Germany</italic>: Walter Karlen</p><p><italic toggle="yes">The University of Melbourne, Australia</italic>: Linda Denehy, Thomas Rollinson</p><p><italic toggle="yes">Mahidol Oxford Tropical Medicine Research Unit, Thailand</italic>: Luigi Pisani, Marcus Schultz</p></sec><sec id="sec020" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0321655.s001" position="float" content-type="local-data"><label>S1 Fig</label><caption><title>Hyperparameter grid search and evaluation strategy.</title><p>Each model was trained on 4 in 5 folds in the whole training set and was used to predict the one held-out fold. All predictions and ground truths on these held-out folds were subsequently concatenated to recover the full training set (herein denoted as pooled validation set) to calculate AUC and CE loss. The hyperparameter set that maximized AUC and minimized CE loss were selected</p></caption><media xlink:href="pone.0321655.s001.pdf"/></supplementary-material><supplementary-material id="pone.0321655.s002" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Definition of hyper-parameters that were grid-searched by cross-validations.</title><p>Values that minimized the validation loss were selected into the final model.</p></caption><media xlink:href="pone.0321655.s002.pdf"/></supplementary-material><supplementary-material id="pone.0321655.s003" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Hyper-parameters for image augmentation that were searched,</title><p>with the results of the grid search reported on column &#x0201c;Value.&#x0201d;</p></caption><media xlink:href="pone.0321655.s003.pdf"/></supplementary-material></sec></body><back><ack><p>We would like to thank all patients and families participating in this study, and all staff at HTD who looked after the patients.</p></ack><glossary><title>List of abbreviation</title><def-list><def-item><term>AUC</term><def><p>Area under the (ROC) curve</p></def></def-item><def-item><term>BA</term><def><p>Balanced accuracy</p></def></def-item><def-item><term>CNN</term><def><p>Convolutional neural network</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>FC</term><def><p>Fully connected (layer)</p></def></def-item><def-item><term>GCS</term><def><p>Glasgow coma score</p></def></def-item><def-item><term>HIV</term><def><p>Human immunodeficiency virus</p></def></def-item><def-item><term>HPC</term><def><p>High performance computing</p></def></def-item><def-item><term>HTD</term><def><p>Hospital for Tropical Diseases</p></def></def-item><def-item><term>IPA</term><def><p>Index of predictive accuracy</p></def></def-item><def-item><term>JADE</term><def><p>Joint Academic Data Science Endeavour</p></def></def-item><def-item><term>MNI</term><def><p>Montreal Neurosciences Institute</p></def></def-item><def-item><term>MRC</term><def><p>(British) Medical Research Council</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance image</p></def></def-item><def-item><term>Mtb</term><def><p>Mycobacterium tuberculosis</p></def></def-item><def-item><term>LR</term><def><p>Learning rate</p></def></def-item><def-item><term>QC</term><def><p>Quality check</p></def></def-item><def-item><term>RCT</term><def><p>Randomised control study</p></def></def-item><def-item><term>ROC</term><def><p>Receiver operating characteristic</p></def></def-item><def-item><term>TB</term><def><p>Tuberculosis</p></def></def-item><def-item><term>TBM</term><def><p>Tuberculous meningitis</p></def></def-item><def-item><term>VITAL</term><def><p>Vietnam Intensive Care Unit Translation Applications Laboratory</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0321655.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Thao</surname><given-names>LTP</given-names></name>, <name><surname>Heemskerk</surname><given-names>AD</given-names></name>, <name><surname>Geskus</surname><given-names>RB</given-names></name>, <name><surname>Mai</surname><given-names>NTH</given-names></name>, <name><surname>Ha</surname><given-names>DTM</given-names></name>, <name><surname>Chau</surname><given-names>TTH</given-names></name>, <etal>et al</etal>. <article-title>Prognostic models for 9-month mortality in tuberculous meningitis</article-title>. <source>Clin Infect Dis</source>. <year>2017</year>;<volume>66</volume>(<issue>4</issue>):<fpage>523</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/cix849</pub-id>
<pub-id pub-id-type="pmid">29029055</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Seddon</surname><given-names>JA</given-names></name>, <name><surname>Tugume</surname><given-names>L</given-names></name>, <name><surname>Solomons</surname><given-names>R</given-names></name>, <name><surname>Prasad</surname><given-names>K</given-names></name>, <name><surname>Bahr</surname><given-names>NC</given-names></name>. <article-title>The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes</article-title>. <source>Wellcome Open Res</source>. <year>2019</year>;<volume>4</volume>:<fpage>167</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15535.1</pub-id>
<pub-id pub-id-type="pmid">32118118</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Dodd</surname><given-names>PJ</given-names></name>, <name><surname>Osman</surname><given-names>M</given-names></name>, <name><surname>Cresswell</surname><given-names>FV</given-names></name>, <name><surname>Stadelman</surname><given-names>AM</given-names></name>, <name><surname>Lan</surname><given-names>NH</given-names></name>, <name><surname>Thuong</surname><given-names>NTT</given-names></name>, <etal>et al</etal>. <article-title>The global burden of tuberculous meningitis in adults: a modelling study</article-title>. <source>PLOS Glob Public Health</source>. <year>2021</year>;<volume>1</volume>(<issue>12</issue>):e0000069. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pgph.0000069</pub-id>
<pub-id pub-id-type="pmid">36962116</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>B</given-names></name>, <name><surname>Fei</surname><given-names>X</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Shang</surname><given-names>D</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Prognostic factors of adult tuberculous meningitis in intensive care unit: a single-center retrospective study in East China</article-title>. <source>BMC Neurol</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>308</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12883-021-02340-3</pub-id>
<pub-id pub-id-type="pmid">34376174</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kee</surname><given-names>CP</given-names></name>. <article-title>Features and prognostic factors of tuberculous meningitis in a tertiary hospital in Malaysia</article-title>. <source>J Infect Dis Epidemiol</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>):<fpage>28</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.23937/2474-3658/1510028</pub-id></mixed-citation></ref><ref id="pone.0321655.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Thao</surname><given-names>LTP</given-names></name>, <name><surname>Wolbers</surname><given-names>M</given-names></name>, <name><surname>Heemskerk</surname><given-names>AD</given-names></name>, <name><surname>Thi Hoang Mai</surname><given-names>N</given-names></name>, <name><surname>Thi Minh Ha</surname><given-names>D</given-names></name>, Thi <name><surname>Hong Chau</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Dynamic prediction of death in patients with tuberculous meningitis using time-updated glasgow coma scale and plasma sodium measurements</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>;<volume>70</volume>(<issue>5</issue>):<fpage>827</fpage>&#x02013;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciz262</pub-id>
<pub-id pub-id-type="pmid">30944929</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Croda</surname><given-names>MG</given-names></name>, <name><surname>Vidal</surname><given-names>JE</given-names></name>, <name><surname>Hern&#x000e1;ndez</surname><given-names>AV</given-names></name>, <name><surname>Dal Molin</surname><given-names>T</given-names></name>, <name><surname>Gualberto</surname><given-names>FA</given-names></name>, <name><surname>Oliveira</surname><given-names>ACPd</given-names></name>. <article-title>Tuberculous meningitis in HIV-infected patients in Brazil: clinical and laboratory characteristics and factors associated with mortality</article-title>. <source>Int J Infect Dis</source>. <year>2010</year>;<volume>14</volume>(<issue>7</issue>):e586&#x02013;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijid.2009.08.012</pub-id>
<pub-id pub-id-type="pmid">20005759</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Hsu</surname><given-names>PC</given-names></name>, <name><surname>Yang</surname><given-names>CC</given-names></name>, <name><surname>Ye</surname><given-names>JJ</given-names></name>, <name><surname>Huang</surname><given-names>PY</given-names></name>, <name><surname>Chiang</surname><given-names>PC</given-names></name>, <name><surname>Lee</surname><given-names>MH</given-names></name>. <article-title>Prognostic factors of tuberculous meningitis in adults: a 6-year retrospective study at a tertiary hospital in Northern Taiwan</article-title>. <source>J Microbiol Immunol Infect</source>. <year>2010</year>;<volume>43</volume>(<issue>2</issue>):<fpage>111</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1684-1182(10)60018-7</pub-id>
<pub-id pub-id-type="pmid">20457427</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>L</given-names></name>, <name><surname>Pang</surname><given-names>X</given-names></name>, <name><surname>Zeng</surname><given-names>Y</given-names></name>, <name><surname>Hao</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <year>et al</year>. <article-title>A clinical scoring model to predict mortality in HIV/TB co-infected patients at end stage of AIDS in China: an observational cohort study</article-title>. <source>BioSci Trends</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>136</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5582/bst.2018.01309</pub-id>
<pub-id pub-id-type="pmid">30930360</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Thuong</surname><given-names>NTT</given-names></name>, <name><surname>Heemskerk</surname><given-names>D</given-names></name>, <name><surname>Tram</surname><given-names>TTB</given-names></name>, <name><surname>Thao</surname><given-names>LTP</given-names></name>, <name><surname>Ramakrishnan</surname><given-names>L</given-names></name>, <name><surname>Ha</surname><given-names>VTN</given-names></name>, <year>et al</year>. <article-title>Leukotriene A4 hydrolase genotype and HIV infection influence intracerebral inflammation and survival from tuberculous meningitis</article-title>. <source>J Infect Dis</source>. <year>2017</year>;<volume>215</volume>(<issue>7</issue>):<fpage>1020</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/infdis/jix050</pub-id>
<pub-id pub-id-type="pmid">28419368</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Wilkinson</surname><given-names>RJ</given-names></name>, <name><surname>Rohlwink</surname><given-names>U</given-names></name>, <name><surname>Misra</surname><given-names>UK</given-names></name>, <name><surname>van Crevel</surname><given-names>R</given-names></name>, <name><surname>Mai</surname><given-names>NTH</given-names></name>, <name><surname>Dooley</surname><given-names>KE</given-names></name>, <year>et al</year>. <article-title>Tuberculous meningitis</article-title>. <source>Nat Rev Neurol</source>. <year>2017</year>;<volume>13</volume>(<issue>10</issue>):<fpage>581</fpage>&#x02013;<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrneurol.2017.120</pub-id>
<pub-id pub-id-type="pmid">28884751</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Hassan</surname><given-names>K</given-names></name>. <article-title>Neurology in tropics</article-title>. <source>Med J Armed Forces India</source>. <year>2000</year>;<volume>56</volume>(<issue>3</issue>):<fpage>271</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0377-1237(17)30196-x</pub-id></mixed-citation></ref><ref id="pone.0321655.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Thwaites</surname><given-names>GE</given-names></name>, <name><surname>Toorn</surname><given-names>RV</given-names></name>, <name><surname>Schoeman</surname><given-names>J</given-names></name>. <article-title>Tuberculous meningitis: more questions, still too few answers</article-title>. <source>Lancet Neurol</source>. <year>2013</year>;<volume>12</volume>:<fpage>999</fpage>&#x02013;<lpage>1010</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70168-6</pub-id>
<pub-id pub-id-type="pmid">23972913</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Thwaites</surname><given-names>GE</given-names></name>, <name><surname>Macmullen-Price</surname><given-names>J</given-names></name>, <name><surname>Chau</surname><given-names>TTH</given-names></name>, <name><surname>Phuong Mai</surname><given-names>P</given-names></name>, <name><surname>Dung</surname><given-names>NT</given-names></name>, <name><surname>Simmons</surname><given-names>CP</given-names></name>, <etal>et al</etal>. <article-title>Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study</article-title>. <source>Lancet Neurol</source>. <year>2007</year>;<volume>6</volume>(<issue>3</issue>):<fpage>230</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1474-4422(07)70034-0</pub-id>
<pub-id pub-id-type="pmid">17303529</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Dian</surname><given-names>S</given-names></name>, <name><surname>Hermawan</surname><given-names>R</given-names></name>, <name><surname>van Laarhoven</surname><given-names>A</given-names></name>, <name><surname>Immaculata</surname><given-names>S</given-names></name>, <name><surname>Achmad</surname><given-names>TH</given-names></name>, <name><surname>Ruslami</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Brain MRI findings in relation to clinical characteristics and outcome of tuberculous meningitis</article-title>. <source>PLoS ONE</source>. <year>2020</year>;<volume>15</volume>(<issue>11</issue>):e0241974. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0241974</pub-id>
<pub-id pub-id-type="pmid">33186351</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Misra</surname><given-names>UK</given-names></name>, <name><surname>Kalita</surname><given-names>J</given-names></name>, <name><surname>Srivastava</surname><given-names>R</given-names></name>, <name><surname>Nair</surname><given-names>PP</given-names></name>, <name><surname>Mishra</surname><given-names>MK</given-names></name>, <name><surname>Basu</surname><given-names>A</given-names></name>. <article-title>A study of cytokines in tuberculous meningitis: clinical and MRI correlation</article-title>. <source>Neurosci Lett</source>. <year>2010</year>;<volume>483</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neulet.2010.07.029</pub-id>
<pub-id pub-id-type="pmid">20691761</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref017"><label>17</label><mixed-citation publication-type="book"><name><surname>Sener</surname><given-names>A</given-names></name>, <name><surname>Erdem</surname><given-names>H</given-names></name>. <source>Extrapulmonary Tuberculosis</source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2019</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/978-3-030-04744-3</pub-id></mixed-citation></ref><ref id="pone.0321655.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Phu</surname><given-names>NH</given-names></name>, <name><surname>Mai</surname><given-names>NTH</given-names></name>, <name><surname>Dung</surname><given-names>LT</given-names></name>, <name><surname>Imran</surname><given-names>D</given-names></name>, <name><surname>Burhan</surname><given-names>E</given-names></name>, <year>et al</year>. <article-title>Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised controlled trial</article-title>. <source>Wellcome Open Res</source>. <year>2018</year>;<volume>3</volume>:<fpage>31</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.12688/wellcomeopenres.14006.2</pub-id>
<pub-id pub-id-type="pmid">30320225</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Khanh</surname><given-names>TDH</given-names></name>, <name><surname>Thwaites</surname><given-names>GE</given-names></name>, <name><surname>Geskus</surname><given-names>RB</given-names></name>. <article-title>A statistical analysis plan for the adjunctive corticosteroids for tuberculous meningitis in HIV-positive adults (ACT HIV) clinical trial</article-title>. <source>Wellcome Open Res</source>. <year>2022</year>;<volume>6</volume>:<fpage>280</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.12688/wellcomeopenres.17154.2</pub-id>
<pub-id pub-id-type="pmid">34778571</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Phu</surname><given-names>NH</given-names></name>, <name><surname>Thao</surname><given-names>LTP</given-names></name>, <name><surname>Lan</surname><given-names>NH</given-names></name>, <name><surname>Mai</surname><given-names>NTH</given-names></name>, <name><surname>Trang</surname><given-names>NTM</given-names></name>, <etal>et al</etal>. <article-title>Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial</article-title>. <source>Wellcome Open Res</source>. <year>2018</year>;<volume>3</volume>:<fpage>32</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.12688/wellcomeopenres.14007.1</pub-id>
<pub-id pub-id-type="pmid">30363837</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Bang</surname><given-names>ND</given-names></name>, <name><surname>Imran</surname><given-names>D</given-names></name>, <name><surname>Nghia</surname><given-names>HDT</given-names></name>, <name><surname>Burhan</surname><given-names>E</given-names></name>, <name><surname>Huong</surname><given-names>DTT</given-names></name>, <etal>et al</etal>. <article-title>Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults</article-title>. <source>NN Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>15</issue>):<fpage>1357</fpage>&#x02013;<lpage>67</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/nejmoa2216218</pub-id>
<pub-id pub-id-type="pmid">37819954</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Heemskerk</surname><given-names>D</given-names></name>, <name><surname>Day</surname><given-names>J</given-names></name>, <name><surname>Chau</surname><given-names>TTH</given-names></name>, <name><surname>Dung</surname><given-names>NH</given-names></name>, <name><surname>Yen</surname><given-names>NTB</given-names></name>, <name><surname>Bang</surname><given-names>ND</given-names></name>, <etal>et al</etal>. <article-title>Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial</article-title>. <source>Trials</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>25</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1745-6215-12-25</pub-id>
<pub-id pub-id-type="pmid">21288325</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Marais</surname><given-names>S</given-names></name>, <name><surname>Thwaites</surname><given-names>G</given-names></name>, <name><surname>Schoeman</surname><given-names>J</given-names></name>, <name><surname>T&#x000f6;r&#x000f6;k</surname><given-names>M</given-names></name>, <name><surname>Misra</surname><given-names>U</given-names></name>, <name><surname>Prasad</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Tuberculous meningitis: a uniform case definition for use in clinical research</article-title>. <source>Lancet Infect Dis</source>. <year>2010</year>;<volume>10</volume>(<issue>11</issue>):<fpage>803</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1473-3099(10)70138-9</pub-id>
<pub-id pub-id-type="pmid">20822958</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Gelman</surname><given-names>A</given-names></name>. <article-title>Scaling regression inputs by dividing by two standard deviations</article-title>. <source>Stat Med</source>. <year>2008</year>;<volume>27</volume>(<issue>15</issue>):<fpage>2865</fpage>&#x02013;<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.3107</pub-id>
<pub-id pub-id-type="pmid">17960576</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>van Buuren</surname><given-names>S</given-names></name>, <article-title>Groothuis-Oudshoorn K.: multivariate imputation by chained equations in R</article-title>. <source>J Stat Soft</source>. <year>2011</year>;<volume>45</volume>(<issue>3</issue>):<fpage>1</fpage>&#x02013;<lpage>67</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18637/jss.v045.i03</pub-id></mixed-citation></ref><ref id="pone.0321655.ref026"><label>26</label><mixed-citation publication-type="other"><collab>R Core Team</collab>. R: a language and environment for statistical computing. <year>2022</year>. Available from: <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="pone.0321655.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Pedregosa</surname><given-names>F</given-names></name>, <name><surname>Varoquaux</surname><given-names>G</given-names></name>, <name><surname>Gramfort</surname><given-names>A</given-names></name>, <name><surname>Michel</surname><given-names>V</given-names></name>, <name><surname>Thirion</surname><given-names>B</given-names></name>, <name><surname>Grisel</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Scikit-learn: machine Learning in Python</article-title>. <source>J Mach Learn Res</source>. <year>2011</year>;<volume>12</volume>:<fpage>2825</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="pone.0321655.ref028"><label>28</label><mixed-citation publication-type="book"><name><surname>Evans</surname><given-names>AC</given-names></name>, <name><surname>Collins</surname><given-names>DL</given-names></name>, <name><surname>Mills</surname><given-names>SR</given-names></name>, <name><surname>Brown</surname><given-names>ED</given-names></name>, <name><surname>Kelly</surname><given-names>RL</given-names></name>, <name><surname>Peters</surname><given-names>TM</given-names></name>. <article-title>3D statistical neuroanatomical models from 305 MRI volumes.</article-title> In: <source>IEEE Conference Record Nuclear Science Symposium and Medical Imaging Conference</source>. NSSMIC-93. <publisher-name>IEEE</publisher-name>; <year>1993</year>. pp. <fpage>1813</fpage>&#x02013;<lpage>7</lpage>. Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.1109/nssmic.1993.373602</pub-id></mixed-citation></ref><ref id="pone.0321655.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Modat</surname><given-names>M</given-names></name>, <name><surname>Cash</surname><given-names>DM</given-names></name>, <name><surname>Daga</surname><given-names>P</given-names></name>, <name><surname>Winston</surname><given-names>GP</given-names></name>, <name><surname>Duncan</surname><given-names>JS</given-names></name>, <name><surname>Ourselin</surname><given-names>S</given-names></name>. <article-title>Global image registration using a symmetric block-matching approach</article-title>. <source>J Med Imaging</source>. <year>2014</year>;<volume>1</volume>(<issue>2</issue>):<fpage>024003</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1117/1.jmi.1.2.024003</pub-id>
<pub-id pub-id-type="pmid">26158035</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Ramachandran</surname><given-names>P</given-names></name>, <name><surname>Zoph</surname><given-names>B</given-names></name>, <name><surname>Le</surname><given-names>QV</given-names></name>. <article-title>Searching for activation functions</article-title>. <source>CoRR</source>. <year>2017</year>; <ext-link xlink:href="https://abs/1710.05941" ext-link-type="uri">https://abs/1710.05941</ext-link></mixed-citation></ref><ref id="pone.0321655.ref031"><label>31</label><mixed-citation publication-type="book"><name><surname>Ginsburg</surname><given-names>B</given-names></name>, <name><surname>Castonguay</surname><given-names>P</given-names></name>, <name><surname>Hrinchuk</surname><given-names>O</given-names></name>, <name><surname>Kuchaiev</surname><given-names>O</given-names></name>, <name><surname>Lavrukhin</surname><given-names>V</given-names></name>, <name><surname>Leary</surname><given-names>R</given-names></name>, <etal>et al</etal>. <source>Stochastic gradient methods with layer-wise adaptive moments for training of deep networks</source>; <year>2019</year>. Available from: <ext-link xlink:href="https://arxiv.org/abs/1905.11286" ext-link-type="uri">https://arxiv.org/abs/1905.11286</ext-link></mixed-citation></ref><ref id="pone.0321655.ref032"><label>32</label><mixed-citation publication-type="book"><collab>MONAI Consortium</collab>. <source>MONAI: medical open network for AI</source>; <year>2022</year>. Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.5281/zenodo.7245821</pub-id></mixed-citation></ref><ref id="pone.0321655.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Holm</surname><given-names>S. A</given-names></name>
<article-title>simple sequentially rejective multiple test procedure</article-title>. <source>Scand J Stat</source>. <year>1979</year>;<volume>6</volume>(<issue>2</issue>):<fpage>65</fpage>&#x02013;<lpage>70</lpage>. Available from: <ext-link xlink:href="https://www.jstor.org/stable/4615733" ext-link-type="uri">https://www.jstor.org/stable/4615733</ext-link></mixed-citation></ref><ref id="pone.0321655.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Steyerberg</surname><given-names>EW</given-names></name>, <name><surname>Vickers</surname><given-names>AJ</given-names></name>, <name><surname>Cook</surname><given-names>NR</given-names></name>, <name><surname>Gerds</surname><given-names>T</given-names></name>, <name><surname>Gonen</surname><given-names>M</given-names></name>, <name><surname>Obuchowski</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Assessing the performance of prediction models: a framework for traditional and novel measures</article-title>. <source>Epidemiology</source>. <year>2010</year>;<volume>21</volume>(<issue>1</issue>):<fpage>128</fpage>&#x02013;<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/ede.0b013e3181c30fb2</pub-id>
<pub-id pub-id-type="pmid">20010215</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>van den Goorbergh</surname><given-names>R</given-names></name>, <name><surname>van Smeden</surname><given-names>M</given-names></name>, <name><surname>Timmerman</surname><given-names>D</given-names></name>, <name><surname>Van Calster</surname><given-names>B</given-names></name>. The <article-title>harm of class imbalance corrections for risk prediction models: illustration and simulation using logistic regression</article-title>. <source>J Am Med Inform Assoc</source>. <year>2022</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1525</fpage>&#x02013;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jamia/ocac093</pub-id>
<pub-id pub-id-type="pmid">35686364</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Smilkov</surname><given-names>D</given-names></name>, <name><surname>Thorat</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>B</given-names></name>, <name><surname>Vi&#x000e9;gas</surname><given-names>F</given-names></name>, <name><surname>Wattenberg</surname><given-names>M</given-names></name>. <article-title>SmoothGrad: removing noise by adding noise</article-title>. <source>arXiv. preprint</source>. <year>2017</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1706.03825</pub-id></mixed-citation></ref><ref id="pone.0321655.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Smilkov</surname><given-names>D</given-names></name>, <name><surname>Thorat</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>B</given-names></name>, <name><surname>Vi&#x000e9;gas</surname><given-names>FB</given-names></name>, <name><surname>Wattenberg</surname><given-names>M</given-names></name>. <article-title>SmoothGrad: removing noise by adding noise</article-title>. <source>CoRR</source>. <year>2017</year>; <ext-link xlink:href="https://abs/1706.03825" ext-link-type="uri">https://abs/1706.03825</ext-link></mixed-citation></ref><ref id="pone.0321655.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Oanh</surname><given-names>PKN</given-names></name>, <name><surname>Dobbs</surname><given-names>N</given-names></name>, <name><surname>Phu</surname><given-names>NH</given-names></name>, <name><surname>Nghia</surname><given-names>HDT</given-names></name>, <name><surname>Summers</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Optic nerve sheath ultrasound for the detection and monitoring of raised intracranial pressure in tuberculous meningitis</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>73</volume>(<issue>9</issue>):e3536&#x02013;<lpage>e3544</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciaa1823</pub-id>
<pub-id pub-id-type="pmid">33283229</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Bang</surname><given-names>ND</given-names></name>, <name><surname>Imran</surname><given-names>D</given-names></name>, <name><surname>Nghia</surname><given-names>HDT</given-names></name>, <name><surname>Burhan</surname><given-names>E</given-names></name>, <name><surname>Huong</surname><given-names>DTT</given-names></name>, <etal>et al</etal>. <article-title>Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>15</issue>):<fpage>1357</fpage>&#x02013;<lpage>67</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/nejmoa2216218</pub-id>
<pub-id pub-id-type="pmid">37819954</pub-id>
</mixed-citation></ref><ref id="pone.0321655.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></name>. rms: regression modeling strategies; <year>2021</year>. Available from: <ext-link xlink:href="https://CRAN.R-project.org/package=rms" ext-link-type="uri">https://CRAN.R-project.org/package=rms</ext-link></mixed-citation></ref><ref id="pone.0321655.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Canas</surname><given-names>LS</given-names></name>, <name><surname>Dong</surname><given-names>THK</given-names></name>, <name><surname>Beasley</surname><given-names>D</given-names></name>, <name><surname>Donovan</surname><given-names>J</given-names></name>, <name><surname>Cleary</surname><given-names>JO</given-names></name>, <name><surname>Brown</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Computer-aided prognosis of tuberculous meningitis combining imaging and non-imaging data</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>17581</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-024-68308-8</pub-id>
<pub-id pub-id-type="pmid">39080381</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0321655.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">28 Oct 2024</named-content>
</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0321655.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Stephen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Stephen Graham</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Stephen Graham</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">28 Nov 2024</named-content>
</p><p><!--<div>-->PONE-D-24-44674<!--</div>--><!--<div>-->Convolutional neural network using magnetic resonance brain imaging to predict outcome from tuberculosis meningitis<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Dong,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by two reviewers below.</p><p>==============================</p><p>Please submit your revised manuscript by Jan 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the&#x000a0;reviewers. You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Steve Graham</p><p>Stephen Michael Graham, FRACP, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p><!--<div>-->Journal requirements:<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->When submitting your revision, we need you to address these additional requirements.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at&#x000a0;<!--</div>--><!--<div>--><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and&#x000a0;<!--</div>--><!--<div>--><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link><!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->2. Thank you for stating the following financial disclosure:&#x000a0;<!--</div>--><!--<div>-->&#x000a0;[T.D, J.D, N.T.T.T, N.T.H, L.S.C, D.B, S.O, R.R, G.E.T, M.M: Wellcome Trust (215010/Z/18/Z, 217650/Z/19/Z, 225167/Z/22/Z),<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->L.S.C, D.B, S.O, R.R, M.M: Wellcome/EPSRC Centre for Medical Engineering (203148/Z/16/Z)<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->All data processing was run on the Wellcome Trust/EPSRC-supported (EP/T022205/1) Joint Academic Data Science Endeavour (JADE) HPC cluster.].&#x000a0;&#x000a0;<!--</div>--><!--<div>-->Please state what role the funders took in the study.&#x000a0; If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""&#x000a0;<!--</div>--><!--<div>-->If this statement is not correct you must amend it as needed.&#x000a0;<!--</div>--><!--<div>-->Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->3. Thank you for stating the following in the Acknowledgments Section of your manuscript:&#x000a0;<!--</div>--><!--<div>-->[We would like to thank all patients and families participating in this study, as well as&#x000a0;<!--</div>--><!--<div>-->all staff at HTD who looked after the patients.&#x000a0;<!--</div>--><!--<div>-->This project received funding from the Wellcome Trust (215010/Z/18/Z), the&#x000a0;<!--</div>--><!--<div>-->Wellcome/EPSRC Centre for Medical Engineering (203148/Z/16/Z), the AI Centre<!--</div>--><!--<div>-->for Value-Based Healthcare, the Vietnam ICU Translation Applications Laboratory&#x000a0;<!--</div>--><!--<div>-->(VITAL) consortium (225167/Z/22/Z) and Oxford University Clinical Research Unit<!--</div>--><!--<div>-->(217650/Z/19/Z). All processing was run on the EPSRC-supported (EP/T022205/1)<!--</div>--><!--<div>-->Joint Academic Data Science Endeavour (JADE) HPC cluster]<!--</div>--><!--<div>-->We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.&#x000a0;<!--</div>--><!--<div>-->Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:&#x000a0;<!--</div>--><!--<div>-->&#x000a0; [T.D, J.D, N.T.T.T, N.T.H, L.S.C, D.B, S.O, R.R, G.E.T, M.M: Wellcome Trust (215010/Z/18/Z, 217650/Z/19/Z, 225167/Z/22/Z),<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->L.S.C, D.B, S.O, R.R, M.M: Wellcome/EPSRC Centre for Medical Engineering (203148/Z/16/Z)<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->All data processing was run on the Wellcome Trust/EPSRC-supported (EP/T022205/1) Joint Academic Data Science Endeavour (JADE) HPC cluster.].&#x000a0;&#x000a0;<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->Please include your amended statements within your cover letter; we will change the online submission form on your behalf.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->4. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>.&#x000a0;<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->Before we proceed with your manuscript, please address the following prompts:<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see<!--</div>--><!--<div>--><ext-link xlink:href="https://journals.plos.org/plosone/s/recommended-repositories" ext-link-type="uri">https://journals.plos.org/plosone/s/recommended-repositories</ext-link>. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->We will update your Data Availability statement on your behalf to reflect the information you provide.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->5. In the online submission form, you indicated that [The datasets used during the current study contain sensitive identifiers from the two clinical trials and thus are available on reasonable request in accordance with the trials data sharing statements. Data are parts of the two randomised control trials: the ACT HIV (identifier NCT03092817) and LAST ACT (identifier NCT03100786). Kindly contact Dr. Joseph Donovan &#x0003c;Joseph.Donovan@lshtm.ac.uk&#x0003e; or Prof. Guy Thwaites &#x0003c;gthwaites@oucru.org&#x0003e; for data sharing permission.].&#x000a0;<!--</div>--><!--<div>-->All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.<!--</div>--><!--<div>-->This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.&#x000a0;<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->6. One of the noted authors is a&#x000a0; consortium [Vietnam ICU Translation Applications Laboratory (VITAL) consortium]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.<!--</div>--></p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->2. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;I Don't Know</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p><!--<font color="black">-->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;I find this manuscript highly interesting and promising, particularly in its potential to enhance the diagnostic utility of MRI as an additional tool for tuberculosis meningitis (TBM). However, I have several comments for consideration:</p><p>Accessibility for Clinicians: The manuscript is highly technical, which may limit its practical application for clinicians in routine care. Simplifying the language and providing more direct clinical insights would enhance its relevance and usability in daily practice.</p><p>Definition of Outcomes: The definition of "events" as outcomes in this paper seems somewhat arbitrary. Death and neurological deficits represent distinct outcomes with a wide range of severity. It would be beneficial for the authors to provide a clear justification for grouping these outcomes together or, alternatively, analyze them separately.</p><p>MRI Findings and Model Explanation: The discussion of the MRI findings and the defined model is insufficiently detailed. The authors should expand on how specific MRI lesions relate to clinical features and outcomes, providing more thorough explanations and discussions to strengthen the paper's conclusions.</p><p>Reviewer #2:&#x000a0;In this manuscript, the authors used a convolutional neural network to predict outcome from tuberculosis meningitis using imaging data only or fused with clinical and laboratory data. This is an interesting study in which the authors show that MRI has additional information in predicting the occurrence of death or neurological complications in the first two months after the MRI.</p><p>However, there are a number of issues that the authors should clarify.</p><p>The study of Canas et al. (ref 40) is using the same dataset and it should be mentioned in the beginning what the difference is with this study since there is clearly some overlap. In the discussion one cannot use this study to discuss similarities since this is expected if you use similar methodology on the same dataset. This part of the discussion should be removed.</p><p>Performance values were compared between the HIV positive and HIV negative group but this is only descriptive and no statistical analysis is performed. Without a proper statistical analysis, we cannot conclude much from a descriptive observation.</p><p>Specific comments</p><p>Figure 1: The arrow in panel C is not very well visible and this can be improved.</p><p>Who checked the quality of the MRI? Was it visually checked by a neuroradiologist? How many scans were excluded? The authors mention that a patient was excluded if no other scan was available as a replacement but this is unclear. Did you included other sequences besides a T1w-MPRAGE or did some patients have multiple scans? If the latter is true, which image was used or were all images used?</p><p>Missing variables were imputed within the training process and this is a valid technique provided that the number of missing data is small compared the collected data. How many missing data were present for the different variables?</p><p>MRI scans were rigidly registered into MNI space but I assume that scaling was applied as well. This could be mentioned explicitly.</p><p>Intensities were normalized to range [0,1]? How was this done exactly? Scaling with respect to the maximum in the image can be a problem depending where this voxel is located.</p><p>It would be interesting to see a correlation matrix between all the non-imaging features. How are features which are highly correlated (if present) handled?</p><p>The caption of figure 2 is very minimal and should be extended.</p><p>It is unclear to me how the vector of 512 imaging features is compressed into a latent vector of length 24.</p><p>P7, line 206: it is mentioned that equation 2 (with alpha = beta = 1) is analogous to concurrently maximizing the likelihood of the three tasks but I am not sure if this is indeed the case. I would expect that this depends on the relative loss with respect to the others.</p><p>P7, line 232: the model was recalibrated by fitting an intercept-only logistic regression on the observed class and the predicted scores as the offset in order to correct for class imbalance. Is there a reference for this procedure showing that this will indeed correct for class imbalance?</p><p>It is not clear what the smooth gradient based saliency maps are representing? Is it some sort of relative weight of a voxel which reflects its contribution to the final output?</p><p>In table 3, event should be replaced by new neurological event (including death) within 2 months or is it representing something else? The age of 24 (1st quartile for the whole group) is different form the value in the text which is 25. I would also add a separate table for the test set to see how representative this test set is.</p><p>P10, line 271 it is mentioned that 79 out of 215 participants (50.2%) were infected with HIV but I don&#x02019;t understand what the 50.2% is representing. 79 out of 215 is much smaller than 50%.</p><p>Is there a reference or an argument why the authors selected some of the hyperparameters such as weight decay at 0.12 for each feature?</p><p>Figure 5: the quality of the figure is poor and values and text were difficult to read. I would also recommend to use the same scale for panels C and D and for panels E and F so that the reader can more easily compare the results of the validation and test set. The n=10 is confusing. I would rather mention the actual number of patients used.</p><p>In figure 6, I do not see coronal planes while this is mentioned in the caption. I would also add a colour bar.</p><p>**********</p><p><!--<font color="black">-->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;<bold>Yes:&#x000a0;</bold>Sofiati Dian., M.D., PhD</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0321655.r003"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r003</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj003" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">7 Jan 2025</named-content>
</p><p>Overall: We would love to express our appreciation to both reviewers for your kind and detailed comments to improve the quality of our manuscript. We acknowledge that there are some issues with the content, as pointed out by the reviewers. We, hence, have carefully taken care of your points of correction and made replies and corrections on our manuscripts, where appropriate. Please kindly find below our point-by-point responses and the related lines in the resubmitted manuscript with tracked changes, as requested by the journal. To produce the tracked change version, we used package `latexdiff` as recommended. Removed text is marked with red colour and strike-through, while added text is marked in blue. Due to the complexity of the table structure, changes made within table cells were not marked automatically. We have highlighted in blue the changes manually.</p><p>We have made point-by-point responses to each reviewer, in a dedicated PDF file, and in text below, where "Q" represents the comment form the Reviewers and "R" represents our Responses. We hope that out responses will be satisfying to the Reviewers. Our deepest apologies to the reviewers for any inconvenience with the aesthetics of the change-tracked file. Please kindly refer to the untracked LaTeX/PDF version for the truly intended visual appearance and structure. I also provide a PDF version of the response letter, in which I noted down the lines where the changes were made.</p><p># Reviewer 1</p><p>- Q: Accessibility for Clinicians: The manuscript is highly technical, which may limit its practical application for clinicians in routine care. Simplifying the language and providing more direct clinical insights would enhance its relevance and usability in daily practice.</p><p>- R: Thank you for your considerate comments. As a clinician by training, I admit that the technical level of this manuscript is quite high, which hampers the accessibility for the clinicals. During the time of writing, we have attempted to balance the technical transparency and the medical impact. However, there are some technical aspects that we cannot sacrifice for the transparency of the methodologies, which also an aspect to determine the credibility of the results.</p><p>However, we agree with the Reviewer that, we need to add some additional medical input to target the clinicians in the field. We have hence added some medical points in the Discussion part, which also associates with your third points.</p><p>- Q: Definition of Outcomes: The definition of "events" as outcomes in this paper seems somewhat arbitrary. Death and neurological deficits represent distinct outcomes with a wide range of severity. It would be beneficial for the authors to provide a clear justification for grouping these outcomes together or, alternatively, analyze them separately.</p><p>- R: Thank you for your concern. The definition of the events in general followed the definition of primary endpoints in the two main RCTs that provided the dataset (ACT HIV and LAST ACT) [20, 21]. In particular, the protocol of LAST ACT stated that &#x0201c;The primary endpoint is death or new neurological event (defined as a fall in Glasgow coma score (GCS) by &#x02265;2 points for &#x02265;2 days from the highest previously recorded GCS (including baseline) or the onset of any of the following clinical adverse events: cerebellar symptoms, focal neurological signs, or new seizures) during 12 months from randomisation.&#x0201d;</p><p>From a clinical perspective, as neurological complications ignited by TBM are, more likely than not, irreversible. Survivors with neurological events during treatment course tend to suffer long-term cognitive impairment and limit in their activities afterwards. The combination of both outcomes highlights that they are both clinically meaningful as a TBM outcome.</p><p>From a modelling perspective, separating the two outcomes would complicate the model, as the two outcomes can be overlapped (those who had neurological events could die consequently), diluting the main objective without much gain in the clinical impact.</p><p>- Q: MRI Findings and Model Explanation: The discussion of the MRI findings and the defined model is insufficiently detailed. The authors should expand on how specific MRI lesions relate to clinical features and outcomes, providing more thorough explanations and discussions to strengthen the paper's conclusions.</p><p>- R: We thank the Reviewer for pointing this out. As the MRI finding, in particular the saliency maps, are purely post hoc analysis without uncertainty estimation, we were extremely careful not to over-interpret the results. We acknowledge that it may be more accessible to the clinician with more clinical input. We therefore added some details regarding our observations from the post hoc analysis and provided some additional details on the corresponding figures.</p><p>However, we also highlight that, these findings are purely observation and not rigorously checked. To overcome this limitation, we also had another paper in plan which leverages brain parcellation to fully segmentate the brain regions. By having a clear definition of brain regions, we can make the interpretation more credible and accessible. This uses a completely different method and will come in a later paper.</p><p># Reviewer 2:</p><p>- Q: The study of Canas et al. (ref 40) is using the same dataset and it should be mentioned in the beginning what the difference is with this study since there is clearly some overlap. In the discussion one cannot use this study to discuss similarities since this is expected if you use similar methodology on the same dataset. This part of the discussion should be removed.</p><p>- R: I would like to express my thank for the Reviewer&#x02019;s comment. Both manuscripts were two parts of a three-part analysis where we performed different investigation on imaging biomarkers for TBM. The datasets indeed shared some overlap, but the methodologies and the outcome were different. In this manuscript, we investigated the short-term outcome during treatment course (6 week) of dexamethasone using only baseline MRI while Liane et.al. used time series MRI to predict long-term quality of life after discharge. Initially, we thought it was of interest to share some similarity in findings using different methods. However, I admitted that the Reviewer&#x02019;s concern is very sensible and understandable. We hence decided to remove the related paragraph from the Discussion.</p><p>- Q: Performance values were compared between the HIV positive and HIV negative group but this is only descriptive and no statistical analysis is performed. Without a proper statistical analysis, we cannot conclude much from a descriptive observation.</p><p>- R: As the sample for the subgroup analysis was small, we constrained ourselves from performing too many statistical testing, because (1) multiplicity correction may bear the risk of nullifying our findings and (2) we did not how to perform correction in this particular case, as the tests were not independent. A potential method is to &#x0201c;pretend&#x0201d; that this was a sequential setup (HIV+ and then HIV-) and performed a Spiessens-Debois correction (<ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/20832503/)" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/20832503/</ext-link>) which exploits the correlation between them to save some error type I. However, this is (1) complicated and (2) not guaranteed to be fully correct.</p><p>We agreed with the Reviewer. Your concern is absolutely valid. We hence therefore added to the Discussion, stating that this comparison is purely speculative.</p><p>- Q: Figure 1: The arrow in panel C is not very well visible and this can be improved.</p><p>- R: Thank you for your comment. We have made the arrow bigger. Please also kindly note that I have noticed that the quality of the figures sent by the journal is not ideal. The original figures had at least 300 dpi &#x02013; usually 600 dpi.</p><p>- Q: Who checked the quality of the MRI? Was it visually checked by a neuroradiologist?</p><p>- R: We (the authors) performed the visual check on the correctness of sequence, artefact (namely Gibbs noise, contrast, bias field, or any irrecoverable deformation) and field of view of the scans (missing slices, invasive crop). We did not check for any lesion appearance as it might bias the analysis. We have TBM clinicians and medical image engineers in the team who had experience with MRI.</p><p>- Q: How many scans were excluded?</p><p>- R: The total number of excluded sessions were 49, amongst which 13 were due to QC failure. The numbers were explicitly mentioned in Fig 4 and on line 275.</p><p>Scan-wise, there were in total 56 T1W scans excluded from the analysis (36 HIV-negative, 20 HIV-positive). In most of the cases, the radiographers would have noticed that the scan were unusable and performed an alternative scan in the same session, explaining the fact that there were more scans excluded than sessions. As there were usually alternative usable scans, we believe that the number of excluded scans was not relevant to the analysis.</p><p>- Q: The authors mention that a patient was excluded if no other scan was available as a replacement but this is unclear. Did you included other sequences besides a T1w-MPRAGE or did some patients have multiple scans? If the latter is true, which image was used or were all images used?</p><p>- R: My apologies we did not make this point clear. We only curated T1w-MPRAGE sequence. If the participants had multiple T1w-MPRAGE sequence, we got the first session, not later than one month (as advised by the TBM experts) nearest to the enrolment date. If there were many T1w-MPRAGE scans in the first session, we got the scan with best quality by manual QC.</p><p>Any T1w-MPRAGE scan that did not pass the manual QC would be excluded. If all T1w-MPRAGE was removed (due to this reason), the patient was excluded.</p><p>If the patient died before any MRI was taken, they weren&#x02019;t included in the analysis.</p><p>- Q: Missing variables were imputed within the training process and this is a valid technique provided that the number of missing data is small compared the collected data. How many missing data were present for the different variables?</p><p>- R: In Table 3 (Baseline Characteristics), column N represented the number of observed data points for that particular variable. An N &#x0003c; 215 would indicate missing data. We apologies that was an implicit representation and we apology for any confusion this may have made. We hence explicitly showed the number of missing points in a dedicated row in Table 3, denoted as &#x0201c;(Missing)&#x0201d;, representing the number of missing data points for the variables preceding it, stratified by HIV status.</p><p>- Q: MRI scans were rigidly registered into MNI space but I assume that scaling was applied as well. This could be mentioned explicitly.</p><p>- R: We sorry for the confusion and have changed the wording to &#x0201c;affine-registered&#x0201d;.</p><p>- Q: Intensities were normalized to range [0,1]? How was this done exactly? Scaling with respect to the maximum in the image can be a problem depending where this voxel is located.</p><p>- R: Thank you. That is a great question. We believe that we need to scale the MRIs into some comparable intensity scale. However, choosing which is still a question under debate. We opted in a trial-error strategy by experimenting with both scaling by range and by standard deviation (sd) before feeding into the neural network.</p><p>For some unknown reason, we found that the model training was more likely to fail with sd-scaled images (stuck and did not move) When it did not fail, we found effectively no difference in performance compared with the range-scaled images. To ensure that the transformation did not corrupt the image, we also visually checked the scaled and registered images for validity before inputting them into the model. We have clarified that in the text.</p><p>In conclusion, we performed the following scaling, where x(i) is the intensity at voxel i: T(x(i))=x(i)/max(x(i))</p><p>- Q: It would be interesting to see a correlation matrix between all the non-imaging features. How are features which are highly correlated (if present) handled?</p><p>- R: This is the correlation between non-imaging continuous features (age, weight, GCS, and CSF lymphocyte count). There are some weak correlations between variables, as shown below.</p><p>age weight gcs csf_lym</p><p>age 1.00 0.12 -0.10 0.09</p><p>weight 0.12 1.00 0.00 0.15</p><p>gcs -0.10 0.00 1.00 0.15</p><p>csf_lym 0.09 0.15 0.15 1.00</p><p>While multicollinearity may interfere the association between the outcome and one particular feature, we expect them to have minimal impact on predictive value of the model (as explained here <ext-link xlink:href="https://stats.stackexchange.com/questions/361247/multicollinearity-and-predictive-performance)." ext-link-type="uri">https://stats.stackexchange.com/questions/361247/multicollinearity-and-predictive-performance</ext-link>). As we did not perform inference on the non-imaging features, we did not perform any correction for multicollinearity.</p><p>As for the inference on the imaging feature, we used SmoothGrad, which is a non-linear technique based on the gradient and not the coefficients. As the gradient was calculated altogether for all feature point (both imaging and non-imaging), any collinearity, in theory, should have been taken into account. However, we are not sure if in practice that statement is true, as it needs further research.</p><p>- Q: The caption of figure 2 is very minimal and should be extended.</p><p>- R: We thank the Reviewer for the great comment. We have extended the figure captions.</p><p>- Q: It is unclear to me how the vector of 512 imaging features is compressed into a latent vector of length 24.</p><p>- R: This is a layer of a feed-forward neural network, effective a matrix multiplication between a matrix whose dimension = 24 x 512 (parameters) and a vector of length 512 (features). See also: <ext-link xlink:href="https://en.wikipedia.org/wiki/Matrix_multiplication" ext-link-type="uri">https://en.wikipedia.org/wiki/Matrix_multiplication</ext-link></p><p>We also made add a vector of 512 into Fig 2 to make this layer more clearly.</p><p>- Q: P7, line 206: it is mentioned that equation 2 (with alpha = beta = 1) is analogous to concurrently maximizing the likelihood of the three tasks but I am not sure if this is indeed the case. I would expect that this depends on the relative loss with respect to the others.</p><p>- R: That is a valid point. We are sorry for the confusion.</p><p>The idea is, as Cross Entropy loss is effective the Negative Log Likelihood of a binomial regression (<ext-link xlink:href="https://en.wikipedia.org/wiki/Cross-entropy#Relation_to_maximum_likelihood)," ext-link-type="uri">https://en.wikipedia.org/wiki/Cross-entropy#Relation_to_maximum_likelihood</ext-link>), summing up the Cross Entropy loss would, in theory, summing up the Negative Log Likelihood.</p><p>As log(x)+log(y) = log(xy), we effective have the log of multiplication of the likelihood.</p><p>Minimising the total Cross Entropy loss would maximise the muliplication of likelihood. If the three tasks are independent, this is translatable to maximising the likelihood function of each tasks, as</p><p>P(A) x P(B) = P(AB) given A&#x00026;B are iid.</p><p>However, we noticed that the three tasks are not mutual independent (only M_img and M_clin are independent), the formula did not translate well to our statement. Therefore, we decided to remove the confusing statement.</p><p>The formulation/treatment is still useful to constrain the model to balancely optimise the two auxilary tasks Lclin and Limg while still make them contribute to the other (by optimising the Lfused).</p><p>However, this formulation comes with a trade-off: the loss of calibration to the large, which is a characteristics of binomial regression when likelihood is maximised (<ext-link xlink:href="https://stats.stackexchange.com/questions/390487/why-is-logistic-regression-well-calibrated-and-how-to-ruin-its-calibration)." ext-link-type="uri">https://stats.stackexchange.com/questions/390487/why-is-logistic-regression-well-calibrated-and-how-to-ruin-its-calibration</ext-link>). We denote this a improper loss function. This is linked to another question of yours that we will discuss below.</p><p>- Q: P7, line 232: the model was recalibrated by fitting an intercept-only logistic regression on the observed class and the predicted scores as the offset in order to correct for class imbalance. Is there a reference for this procedure showing that this will indeed correct for class imbalance?</p><p>- R: Thank you very much for pointing this out, this is a typing mistake from us. It should be &#x0201c;to correct for improper loss function&#x0201d;. We have made the change accordingly.</p><p>As discussed above, combining the losses makes the model miscalibrated due to a bias loss. This may hold true (but not as severe) with Ridge loss in penalised logistic regression. The level of miscalibration depends on the penalty term value, whic</p><supplementary-material id="pone.0321655.s004" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.pdf</named-content></p></caption><media xlink:href="pone.0321655.s004.pdf"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0321655.r004" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r004</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Stephen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Stephen Graham</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Stephen Graham</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj004" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">28 Jan 2025</named-content>
</p><p>&#x0003c;div&#x0003e;PONE-D-24-44674R1<!--</div>--><!--<div>-->Convolutional neural network using magnetic resonance brain imaging to predict outcome from tuberculosis meningitis<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Dong.</p><p>Apologies for delay but was awaiting comments from a second reviewer who previously reviewed. Given time lapse, I have decided&#x000a0;to proceed with comments of the one reviewer who has again carefully reviewed your manuscript. Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Mar 14 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p><!--<div>-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Steve</p><p>Stephen Michael Graham, FRACP, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!--</font>--></p><p>Reviewer #1:&#x000a0;All comments have been addressed</p><p>**********</p><p><!--<font color="black">-->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;I Don't Know</p><p>**********</p><p><!--<font color="black">-->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;No</p><p>**********</p><p><!--<font color="black">-->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;First, the author has tried to address all the reviewer's comments and requests; however, the absence of a tracked changes file makes it more challenging to follow the revisions.</p><p>Secondly, the overall clinical applicability of the article remains limited, potentially making it more relevant to a statistical audience than to clinicians. The extensive focus on methodology may diminish its practical value for clinical implementation. I recommend that the author revise the article's objective, replacing phrases such as "predict the occurrence of any neurological complication" or "expand the insight in clinical prognostications" with a more technically precise and focused expression. Alternatively, the author could enhance the article by including clear clinical conclusions in the first paragraph of the discussion and elaborating on the clinical implications in the conclusion section at the end of the discussion.</p><p>**********</p><p><!--<font color="black">-->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;<bold>Yes:&#x000a0;</bold>Sofiati Dian</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.<!--</div>--></p></body></sub-article><sub-article article-type="author-comment" id="pone.0321655.r005"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r005</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj005" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">9 Mar 2025</named-content>
</p><p>Dear Reviewer,</p><p>We appreciate the Reviewer&#x02019;s comment and agree that the previous version of the manuscript placed a significant emphasis on the method, mainly for transparency and reproducibility purposes. In summary, the Reviewer made two points: the lack of a tracked-changes version (point 1) and the overly focus on methodology (point 2). We will first focus on point 2, which is the primary concern of the Reviewer.</p><p>For point 2, we agree that this overfocus on methodology might have given the manuscript a less attractive position to clinical readers. Please kindly note that while our proposed approach and full framework are novel in their application to the present clinical problem of tuberculous meningitis, the core model itself is not entirely new and has been applied to other diseases. To address that point, and by aiming to refocus the paper on its clinical contribution, we have moved details regarding the method to supplementary material, from both the Methods and Results sections as follows:</p><p>- Table 2 moves to the Supplementary document and becomes Supplementary Table S1.</p><p>- Table 5 moves to the Supplementary document and becomes Supplementary Table S2.</p><p>- Figure 3 moves to the Supplementary document and becomes Supplementary Figure S1.</p><p>Furthermore, to emphasise the clinical value of our findings, we have modified the Discussion to describe better the clinical conclusions aroused from our results, as kindly suggested by the Reviewer, as follows:</p><p>- In the first paragraph, we have reiterated the clinical context and challenges that motivated our study.</p><p>- In the second paragraph, we have restated our clinical objective and introduced the main clinical results for the objective.</p><p>- In the third to eighth paragraphs, we discussed the results in detail.</p><p>- In the ninth to fourteenth paragraphs, we discussed our pros and cons.</p><p>- In the last paragraph, we reiterated our study and clinical impact.</p><p>We hope this addresses the Reviewer&#x02019;s main concerns and makes our study message clearer to the journal audience.</p><p>For point 1 made by Reviewer regarding the absence of a tracked-change file, please kindly accept our deepest apologies. We have contacted the journal's editor. However, they did not find any issues. Please kindly find a PDF document with the name &#x0201c;Revised Manuscript with Track Changes.pdf&#x0201d;. If you are receiving a long PDF file with all the forms, manuscript, and download links to supplementary documents embedded, please kindly scroll down to the near bottom. I would assume you can find the tracked-changes version there, followed by a PDF version of this Response letter. For some strange reason, I am not allowed to reorder the documents when I uploaded. In the case it does not appear on your side, please kindly contact the editor or the journal, since the existence of this file is mandated by them during the resubmission process. For the resolution of the figures, please kindly find in the attached file Figure.zip where Figures are sent in their original resolution. The downscaling of the figures was not intentional. Please kindly refer to the untracked LaTeX/PDF version for the true intended visual appearance and structure.</p><p>With best regards,</p><supplementary-material id="pone.0321655.s005" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers_auresp_2.pdf</named-content></p></caption><media xlink:href="pone.0321655.s005.pdf"/></supplementary-material></body></sub-article><sub-article article-type="editor-report" id="pone.0321655.r006" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r006</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Stephen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Stephen Graham</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Stephen Graham</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj006" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">10 Mar 2025</named-content>
</p><p>Convolutional neural network using magnetic resonance brain imaging to predict outcome from tuberculosis meningitis</p><p>PONE-D-24-44674R2</p><p>Dear Dr. Trinh Dong,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link>&#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Steve</p><p>Stephen Michael Graham, FRACP, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p></body></sub-article><sub-article article-type="editor-report" id="pone.0321655.r007" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0321655.r007</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Stephen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Stephen Graham</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Stephen Graham</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0321655" id="rel-obj007" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-24-44674R2</p><p>PLOS ONE</p><p>Dear Dr. Dong,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Stephen Michael Graham</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>